Formulation and Evaluation of Sustained-Release Matrix Tablets of Timolol Maleate. by Garlapati, Ayyappa
FORMULATION AND EVALUATION OF SUSTAINED-RELEASE 
MATRIX TABLETS OF TIMOLOL MALEATE 
 
A dissertation submitted to 
THE TAMILNADU Dr. M.G.R.MEDICAL UNIVERSITY, CHENNAI. 
 
In partial fulfillment of the requirements for the award of degree of 
MASTER OF PHARMACY 
IN PHARMACEUTICS 
BY 
REG .NO:26091385 
 
Under the guidance of 
Prof.S.P.SENTHIL, M.PHARM.,(Ph.D.,) 
Department of   Pharmaceutics 
 
 
 
 
 
OCTOBER-2011 
THE ERODE COLLEGE OF PHARMACY & RESEARCH INSTITUTE 
ERODE -638112, TAMILNADU. 
  
 
 
 
 
DEDICATED 
TO 
My 
Beloved Family, 
 Teachers & Friends  
 
 
 
 
 
 
  
Certificates 
The Erode College Of Pharmacy & Research Institute 
Prof.S.P.SENTHIL, M.Pharm.,( Ph.D.,) 
Department of pharmaceutics,                                                     
Perundurai Main Road, 
 Veppampalayam,  
 Erode-638112, India. 
e-mail : senthilumasenthil@yahoo.co.in 
 
 
CERTIFICATE 
 
           This is to certify that the investigation in this thesis entitled “FORMULATION 
AND EVALUATION OF SUSTAINED-RELEASE MATRIX TABLETS 
OF TIMOLOL MALEATE” submitted to The Tamilnadu Dr. M.G.R. Medical 
University Chennai. For partial fulfillment of the award of degree of Master of pharmacy in 
pharmaceutics was carried out by Reg .No.26091385 in the department of pharmaceutics, 
The Erode College of pharmacy, Erode, under my guidance and supervision  
            This work is original and has not been submitted in part or full to any other degree or 
diploma of this or any other university.  
 
 
 
                                                                      
 
Place: Erode                                                   Prof. S.P.SENTHIL, M.Pharm.,(Ph.D.,)                                                             
Date:                                                                            
 
 
 
 
 
The Erode College Of Pharmacy & Research Institute 
Dr.V.Ganesan, M.Pharm., Ph.D.,  
Professor and HOD of Pharmaceutics, 
Perundurai Main Road, 
Veppampalayam,  
Erode – 638112.                                          
 
CERTIFICATE 
This is to certify that the investigation in this thesis entitled “FORMULATION AND 
EVALUATION OF SUSTAINED – RELEASE MATRIX TABLETS OF TIMOLOL 
MALEATE” submitted to the Tamil Nadu Dr. M.G.R Medical University, Chennai, for the 
partial fulfillment of the award of Degree of Master of Pharmacy in Pharmaceutics, was 
carried out by Regd. No. 26091385 in the Department of Pharmaceutics, under the guidance 
of Prof. S.P. Senthil, M.Pharm., (Ph.D.,) The Erode College of Pharmacy and Research 
Institute, Erode 638112. 
  This work is original and has not been submitted in part or full to any other degree or 
diploma of this or any other university. 
 
 
 
Place:  Erode                              
Date:         Dr.V.Ganesan, M.Pharm., Ph.D.,  
    
 
    
 
 
 
 
 
 
 
 
 
ENDORSEMENT BY THE PRINCIPAL 
 
 
 
 
 
 
                     
This is to certify that the investigation in this thesis entitled “FORMULATION AND 
EVALUATION OF SUSTAINED – RELEASE MATRIX TABLETS OF TIMOLOL 
MALEATE” submitted in partial fulfillment of the requirements for the Degree Of 
MASTER OF PHARMACY in PHARMACEUTICS were carried out in the 
pharmaceutics laboratories of The Erode College Of Pharmacy and Research Institute, Erode 
by Regd.No.26091385 under the guidance of Prof. S.P.Senthil,  M.Pharm.,(Ph.D.,), 
Dept. of Pharmaceutics, The Erode College Of Pharmacy and Research Institute, Erode. 
 
 
 
 
Place: Erode 
Date:          PRINCIPAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DECLERATION 
 
   
The research work embodied in this dissertation work entitled 
“FORMULATION AND EVALUATION OF SUSTAINED – RELEASE MATRIX 
TABLETS OF TIMOLOL MALEATE ” was carried out by me in the Department of 
Pharmaceutics, The Erode College of Pharmacy, Erode, under the direct supervision 
of  Prof. S.P.Senthil,  M.Pharm.,(Ph.D.,), Dept. of Pharmaceutics, The Erode 
College of Pharmacy, Erode – 638 112. 
 This dissertation submitted to The TamilNadu Dr. M.G.R Medical 
University, Chennai, as a partial fulfillment for the award of degree of Master of 
Pharmacy in Pharmaceutics during the academic year 2009 – 2011. 
 The work is original and has not been submitted in part or full for the award 
of any other Degree or Diploma of this or any other University. 
 
 
Place : Erode                                   
Date :                                                 Reg. No. 26091385 
  
 
 
 
ACKNOWLEDGEMENT 
The joyness , satisfaction and euphoria that come along with 
successful completion of any work would be incomplete unless we mention 
the names of the people who made it possible, whose constant guidance and 
encouragement served as a beam of light and crowned out the efforts. 
First of all, it is by the love and blessings of God Almighty that I am 
able to complete my investigation studies successfully and I present this 
piece of work which I am eternally indebted. 
I am extremely grateful to my research guide                        
Prof.S.P.Senthil, M. Pharm.,(Ph.D.,),Department of Pharmaceutics, The 
Erode College of Pharmacy, for his valuable guidance, co-operation, 
affectionate encouragement and moral support through out the course of my 
research work. 
I now take this oppurtunity to express sincere thanks to                
Dr.V.Ganesan, M.Pharm., Ph.D., Principal, The Erode College of Pharmacy, 
Erode for his valuable guidance and constant encouragement.  
My sincere thanks to Mrs.T.Sudhamani,M.Pharm., and 
Mrs.Allimalarkodi,M.Pharm.,Department of Pharmaceutics, for their their 
valuable support.  
I am very thankfull to Dr.V.S.Sarvanan, M.Pharm.Ph.D.,  
Dr.C.T.Kumarappan M.Pharm, Ph.D., Dr.P.Vijaypandi, D.S.M., M.Pharm., 
Ph.D., Mr.T.Ethiraj, M.pharm, Mrs.T.Revathi, M.pharm., and All Staff 
Members, The Erode College Of Pharmacy,for their valuable suggestions 
throught the duration of my course. 
I also express my thanks to our NON TEACHING STAFF,LIBRARY 
STAFF and OFFICE STAFF for providing timely assistance through out 
entire work. 
I would like to extend my thanks to my M. Pharm. Classmates        
NoveeenkumarReddy, MallikaarjunaReddy, Phaniradhakrishna, 
Appalaraju, Ramkumar and Ismael  for their support and 
encouragement through out the study.I am very thankful to my dear 
most friends Vijay,Barath, Sandip Chemthe, Sandeep Raju, sada, 
prasanth, balan, rangith, srinu and my senior Ajith Chandra  and my 
juniors from M.Pharm and B.Pharm. 
Words fail me to express the heartfelt reverence & gratitude I feel 
towards my, family members, to whom I owe all I achieved in life. Their 
words of encouragement always helped me to keep moving on. If anybody 
asked which is golden period of your life. I will say without any hesitation 
that, “My whole life is a golden period because of degree of freedom and 
love I received from my family”. 
Last but not the least I express my sincere thanks to one and all who gave 
constant encouragement and help throughout my educational career.  
Date : 
Place :Erode                                          Reg. No. 26091385 
 Thesis 
Contents 
TABLE OF CONTENTS 
                                                                                                       
   
 
 
 
 
 
 
 
 
 
 
 
 
S. No. Chapter Name Page No. 
1 Introduction 1 
2 Review of Literature 24 
3 Research Envisaged  30 
4 Drug Profile 34 
5 Polymer and Excipient 
Profile 
40 
6 Methodology 49 
7 Results  69 
8 Discussion 96 
9 Summary & Conclision 102 
10 References 105 
                                                                                                    Abbrevations 
 
 
Dept ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode  
 
ABBREVIATIONS 
 
ACE Angiotensin -Converting Enzyme 
BP British Pharmacopoeia 
cm                                              Centimeter 
Conc. Concentration 
cps Centipoises 
CRDDS                               Controlled Release Drug Delivery System 

C Degree Centigrade 
EC Ethylcellulose 
F  Formulation 
FTIR  Fourier Transform Infrared Spectroscopy 
g                                               Gram 
GIT                                          Gastrointestinal tract 
h  Hour 
HCl  Hydrochloric acid 
HPMC Hydroxypropylmethylcellulose 
IP                                              Indian Pharmacopoeia 
IPA                                           Isopropyl alcohol 
                                                                                                    Abbrevations 
 
 
Dept ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode  
 
ISA Intrinsic sympathomimetic activity 
Kg   Kilogram 
LD                                            Lethal Dose 
LR Laboratory Reagent 
MCC Microcrystalline cellulose 
mcg  Microgram 
MDT                                         Mean dissolution time 
MEC                                         Minimum Effective Concentration 
mg Milligram 
min Minute 
mL Milliliter 
mPa s Milli Pascal Second 
MS                                           Magnesium Stearate 
MSC                                        Maximum Safe Concentration 
n Diffusion coefficient 
N Normality 
nm Nanometer 
No.                                           Number 
PEO Polyethylene Oxide 
PVP Polyvinylpyrrolidone 
                                                                                                    Abbrevations 
 
 
Dept ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode  
 
RH Relative Humidity 
rpm  Revolutions per minute 
SD                                            Standard Deviation 
S. No.  Serial Number 
SR Sustained-Release 
TM                                                  Timolol Maleate 
USP  United States Pharmacopoeia 
UV  Ultraviolet 
w/w  Weight by weight 
m Micrometer 
%  Percentage 
β Beta 
 
LIST OF TABLES 
 
 
S. No. Title of the Table Page. No. 
1 Examples of Oral Extended-Release Products 7 
2 Technologies Used for CRDDS 12 
3 Classification of Matrix Systems 14 
4 Drug Release Kinetics 18 
5 List of Different Formulations                    55 
6 Composition of Matrix Tablets Containing HPMC K15M 56 
7 Composition of Matrix Tablets Containing PEO 56 
8 Composition of Matrix Tablets Containing HPMC K100M  57 
9 Composition of Matrix Tablets Containing Ethylcellulose 57 
10 Composition of Matrix Tablets Containing Kollidon
® 
SR 57 
11 
Composition of Matrix Tablets Containing Combination of  
HPMC K100M and EC 
58 
12 
Composition of Matrix Tablets Containing Combination of  
HPMC K100M and HPMC K15M 
58 
13 Significance of Angle Of Repose 59 
14 Carr’s Index Values  61 
15 Significance of Hausener’s Ratio 61 
       16 
Diffusion Exponent and Solute Release Mechanism for 
Cylindrical Shape 
66 
17 Standard Graph of Timolol Maleate 69 
18 
Theoretical Release Profile of Timolol Maleate from SR 
Tablets 
71 
19 Physical Properties of Precompression Blend  72 
20 Physical Evaluation of Matrix Tablets 
73 
 
21 
In-Vitro Release Data of Timolol Maleate from HPMC K15M 
Matrices 
75 
22 
In-Vitro Release Data of Timolol Maleate from Polyethylene 
Oxide Matrices 
77 
23 
In -Vitro Release Data of Timolol Maleate from HPMC 
K100M CR Matrices 
78 
24 
In-Vitro Release Data of Timolol Maleate from Ethylcellulose 
Matrices 
 
79 
25 
In-Vitro Release Data of Timolol Maleate from Kollidon-SR 
Matrices 
80 
26 
In -Vitro Release Data of Timolol Maleate from Tablets  
Containing HPMC K100M CR and Ethylcellulose 
 
82 
27 
In-Vitro Release Data of Timolol Maleate from Tablets 
Containing HPMC K100M and HPMC K15M 
 
83 
28 Drug Release Kinetics of Batch (F12) Matrix Tablets 84 
29 Drug Release Kinetics of Optimized (F23) Matrix Tablets 85 
30 Similarity Factor Analysis 88 
31 Swelling and Erosion Study of Optimized Formulation (F23) 89 
32 Accelerated stability studies data 93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LIST OF FIGURES 
 
S. No. Title of the Figure Page No. 
1 
A Hypothetical Plasma Concentration-Time Profile from 
Conventional Multiple Dosing and Single Doses of Sustained 
and Controlled Delivery Formulations.  
2 
2 
Schematic Drug Release from Matrix Diffusion Controlled-
Release Drug Delivery Systems 
15 
3 Standard Graph of Timolol Maleate in 0.1 N HCl 70 
4 Standard Graph of Timolol Maleate in 6.8 pH Buffer 70 
5 
Release Profile of Timolol Maleate from HPMC K15M 
Matrices 
76 
6 
Release Profile of Timolol Maleate from Polyethylene Oxide 
Matrices 
77 
7 
Release Profile of Timolol Maleate from HPMC K100M 
Matrices 
79 
8 
Release Profile of Timolol Maleate from Ethylcellulose 
Matrices 
80 
9 
Release Profile of Timolol Maleate from Kollidon-SR 
Matrices 
81 
10 
Release Profile of Timolol Maleate from Tablets Containing 
HPMC K100M CR and Ethylcellulose 
82 
11 
Release Profile of Timolol Maleate from Tablets Containing 
HPMC K100M and HPMC K15M 
83 
12 Zero Order Graph of Optimized Formulation (F23)  85 
13 First Order Graph of Optimized Formulation (F23) 85 
14 Higuchi Plot of Optimized Formulation (F23) 86 
15 Korsmeyer-Peppas Graph of Optimized Formulation  (F23) 86 
16 Hixson-Crowell  Plot of Optimized Formulation (F23) 87 
17 
Comparative In-Vitro Drug Release Profile  
88 
18 
 Swelling Study of Optimized Formulation (F23) 
89 
19 
Erosion Study of Optimized Formulation (F23) 
90 
20 
Accelerated Stability Studies-Dissolution 
94 
21 
Accelerated Stability Studies-Assay 
95 
 
LIST OF SPECTRA 
S. No. Name of the Spectrum Page No. 
1 FTIR Spectrum of Timolol Maleate 91 
2 FTIR Spectrum of Optimized Formulation (F23) 92 
 
 Chapter 1 
Introduction 
 Chapter-1                                                                                                    Introduction 
Dept ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode Page 1 
1. INTRODUCTION 
 Most conventional oral drug products, such as tablets and capsules, are 
formulated to release the active drug immediately after oral administration, to obtain 
rapid and complete systemic drug absorption. Such immediate-release products result 
in relatively rapid drug absorption and onset of accompanying pharmacodynamic 
effects. However, after absorption of the drug from the dosage form is complete, 
plasma drug concentrations decline according to the drug's pharmacokinetic profile. 
Eventually, plasma drug concentrations fall below the minimum effective plasma 
concentration (MEC), resulting in loss of therapeutic activity. Before this point is 
reached, another dose is usually given if a sustained therapeutic effect is desired. An 
alternative to administering another dose is to use a dosage form that will provide 
sustained drug release, and therefore maintain plasma drug concentrations, beyond 
what is typically seen using immediate-release dosage forms. In recent years, various 
modified-release drug products have been developed to control the release rate of the 
drug and/or the time for drug release.  
             The term modified-release drug product is used to describe products that alter 
the timing and/or the rate of release of the drug substance. A modified-release dosage 
form is defined "as one for which the drug-release characteristics of time course 
and/or location are chosen to accomplish therapeutic or convenience objectives not 
offered by conventional dosage forms such as solutions, ointments, or promptly 
dissolving dosage forms as presently recognized".  
            Several types of modified-release drug products are recognized (Leon Shargel 
et al., 2004). 
Extended-release drug products: A dosage form that allows at least a twofold 
reduction in dosage frequency as compared to that drug presented as an immediate-
release (conventional) dosage form. Examples of extended-release dosage forms 
include controlled-release, sustained-release, and long-acting drug products.  
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Delayed-release drug products: A dosage form that releases a discrete portion or 
portions of drug at a time or at times other than promptly after administration, 
although one portion may be released promptly after administration. Enteric-coated 
dosage forms are the most common delayed-release products.  
Targeted-release drug products. A dosage form that releases drug at or near the 
intended physiologic site of action. Targeted-release dosage forms may have either 
immediate- or extended-release characteristics. 
The term controlled-release drug product was previously used to describe 
various types of oral extended-release-rate dosage forms, including sustained-release, 
sustained-action, prolonged-action, long-action, slow-release, and programmed drug 
delivery.  
1.1. Conventional Drug Delivery System 
Pharmaceutical products designed for oral delivery are mainly conventional 
drug delivery systems, which are designed for immediate release of drug for 
rapid/immediate absorption (Robinson, 1987). 
As can be seen in the graph (Figure 1), administration of the conventional 
dosage form by extra vascular route does not maintain the drug level in blood for an 
extended period of time. The short duration of action is due to the inability of 
conventional dosage form to control temporal delivery. 
 
Fig. 1.   A hypothetical plasma concentration-time profile from conventional multiple 
dosing and single doses of sustained and controlled delivery formulations. (MSC = 
maximum safe concentration, MEC = minimum effective concentration). 
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The conventional dosage forms like solution; suspension, capsule, tablets and 
suppository etc. have some limitations such as 
1) Drugs with short half-life require frequent administration, which increases 
chances of missing the dose of drug leading to poor patient compliance. 
2) A typical peak-valley plasma concentration-time profile is obtained which makes 
attainment of steady state condition difficult. The unavoidable fluctuations in the 
drug concentration may lead to under medication or overmedication as the steady 
state concentration values fall or rise beyond the therapeutic range.  
3) The fluctuating drug levels may lead to precipitation of adverse effects especially 
of a drug with small therapeutic index, whenever overdosing occurs.  
In order to overcome the drawbacks of conventional drug delivery systems, 
several technical advancements have led to the development of controlled drug 
delivery system that could revolutionize method of medication and provide a number 
of therapeutic benefits (Chien, 1992). 
1.2. Controlled Release Drug Delivery Systems (CRDDS) 
More precisely, controlled delivery can be defined as 
1) Sustained drug action at a predetermined rate by maintaining a relatively constant, 
effective drug level in the body with concomitant minimization of undesirable 
side effects. 
2) Localized drug action by spatial placement of a controlled release system adjacent 
to or in the diseased tissue.  
3) Targeted drug action by using carriers or chemical derivatives to deliver drug to a 
particular target cell type.  
4) Provide a physiologically / therapeutically based drug release system. In other 
words, the amount and the rate of drug release are determined by the 
physiological/ therapeutic needs of the body.  
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A controlled drug delivery system is usually designed to deliver the drug at 
particular rate. Safe and effective blood levels are maintained for a period as long as 
the system continues to deliver the drug. This predetermined rate of drug release is 
based on the desired therapeutic concentration and the drug’s pharmacokinetics.  
Advantages of Controlled Drug Delivery System  
1. Overcome patient compliance problems.  
2. Employ less total drug  
a) Minimize or eliminate local side effects 
b) Minimize or eliminate systemic side effects  
c) Obtain less potentiation or reduction in drug activity with chronic use. 
d) Minimize drug accumulation with chronic dosing.  
3. Improve efficiency in treatment  
a) Cures or controls condition more promptly. 
b) Improves control of condition i.e., reduced fluctuation in drug level. 
c) Improves bioavailability of some drugs. 
d) Make use of special effects, e.g. Sustained-release aspirin for morning relief of 
arthritis by dosing before bed time.  
4. Economy i.e. reduction in health care costs. The average cost of treatment over an 
extended time period may be less, with lesser frequency of dosing, enhanced 
therapeutic benefits and reduced side effects. The time required for health care 
personnel to dispense and administer the drug and monitor patient is also reduced.  
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Disadvantages 
1) Decreased systemic availability in comparison to immediate release conventional 
dosage forms, which may be due to incomplete release, increased first-pass 
metabolism, increased instability, insufficient residence time for complete 
release, site specific absorption, pH dependent stability etc.  
2) Poor in vitro – in vivo correlation.  
3) Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity 
reactions.  
4) Reduced potential for dose adjustment of drugs normally administered in varying 
strengths (Hoffman, 1998). 
1.3. Oral Controlled Drug Delivery Systems  
Oral controlled release drug delivery is a system that provides continuous oral 
delivery of drugs at predictable and reproducible kinetics for a predetermined period 
throughout the course of GI transit and also the system that target the delivery of a 
drug to a specific region within the GI tract for either a local or systemic action (Vora 
et al., 1996). 
Classification of Oral Controlled Release Systems  
A) Diffusion Controlled Systems 
I.  Reservoir Devices. 
 A core of drug (the reservoir) surrounded by a polymeric membrane 
characterizes them. The nature of the membrane determines the rate of drug release. 
The characteristics of reservoir diffusion systems are 
1. Zero order drug release is possible. 
2. The drug release rate is dependent on the type of polymer. 
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3. High molecular weight compounds are difficult to deliver through the device. 
Coating and microencapsulation technique can be used to prepare sub devices. 
II.  Matrix Devices. 
  It consists of drug dispersed homogeneously in a matrix. The characteristics of 
the matrix diffusion system is 
1. Zero order release cannot be obtained. 
2. Easy to produce than reservoir devices. 
3. High molecule weight compounds are delivered through the devices. 
B) Dissolution controlled systems 
I. Matrix Dissolution Controlled System 
  Aqueous dispersions, congealing, spherical agglomeration etc. can be used.   
II.    Encapsulation Dissolution Control 
  Particles, seeds or granules can be coated by technique such as 
microencapsulation. 
C) Diffusion and Dissolution Controlled System. 
  In a bioerodible matrix, the drug is homogenously dispersed in a matrix and it 
is released either by swelling controlled mechanism or by hydrolysis or by enzymatic 
attack. 
1.4. Types of Extended-Release Products 
 General approaches to manufacturing an extended-release drug product 
include the use of a matrix structure in which the drug is suspended or dissolved, the 
use of a rate-controlling membrane through which the drug diffuses, or a combination 
of both. Among the many types of commercial preparations available, none works by 
a single drug-release mechanism. Most extended-release products release drug by a 
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combination of processes involving dissolution, permeation, and diffusion. The single 
most important factor is water permeation, without which none of the product release 
mechanisms would operate. Controlling the rate of water influx into the product 
generally dictates the rate at which the drug dissolves. Once the drug is dissolved, the 
rate of drug diffusion may be further controlled to a desirable rate. Table 1 shows 
some common extended-release product examples and the mechanisms for controlling 
drug release, and lists the compositions for some drugs (Leon Shargel, 2004).                                        
Table 1.  Examples of Oral Extended-Release Products 
Type Trade Name Rationale 
Erosion tablet 
  
  
Constant-T Theophylline  
Tenuate 
Dospan 
Diethylpropion HCl dispersed in hydrophilic 
matrix 
Tedral SA Combination product with a slow-erosion 
component (theophylline, ephedrine HCl) and 
an initial-release component theophylline, 
ephedrine HCl, phenobarbital) 
Waxy matrix tablet Kaon Cl   Slow release of potassium chloride to reduce 
GI irritation 
Coated pellets in 
capsule 
Ornade 
spansule 
Combination phenylpropanolamine HCl and 
chlorpheniramine with initial- and extended-
release component 
Pellets in tablet Theo-Dur Theophylline  
Leaching 
  
Ferro-
Gradumet 
(Abbott) 
Ferrous sulfate in a porous plastic matrix that is 
excreted in the stool; slow release of iron 
decreases GI irritation 
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Desoxyn 
gradumet 
tablet 
(Abbott) 
Methamphetamine methylacrylate 
methylmethacrylate copolymer, povidone, 
magnesium stearate; the plastic matrix is 
porous 
Coatedion 
exchange 
Tussionex Cation ion-exchange resin complex of 
hydrocodone and phenyltoloxamine 
Flotation–diffusion Valrelease Diazapam 
Osmotic delivery 
  
Acutrim Phenylpropanolamine HCl (Oros delivery 
system) 
Procardia-XL GITS—gastrointestinal therapeutic system with 
NaCl-driven (osmotic pressure) delivery 
system for nifedipine  
Microencapsulation 
  
  
Bayer timed-
release 
Aspirin 
Nitrospan Microencapsulated nitroglycerin  
Micro-K 
Extencaps 
Potassium chloride microencapsulated particles 
1.5. Factors Influencing the Design and Performance of Sustained Release     
Products 
          The type of delivery system and route of administration of the drug presented in 
sustained drug delivery system may depend upon two properties (Bramhankar and 
Jaiswal, 1995). They are 
I. Physicochemical Properties of drugs 
II. Biological Factors. 
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I. Physicochemical Properties of Drugs 
1. Dose size  
For orally administered systems, there is an upper limit to the bulk size of the 
dose to be administered. In general a single dose of 0.5 to 1gm is considered 
maximum (Nicholas et al., 1987). 
2. Ionization, P
Ka
 & Aqueous Solubility  
 The pH Partition hypothesis simply states that the unchanged form of a drug 
species will be preferentially absorbed through many body tissues. Therefore it is 
important to note the relationship between the P
Ka
 of the compound and its absorptive 
environment. For many compounds, the site of maximum absorption will also be the 
area in which the drug is least soluble. 
                   For conventional dosage forms the drug can generally fully dissolve in the 
stomach and then be absorbed in the alkaline pH
 
of the intestine. For sustained release 
formulations much of the drug will arrive in the small intestine in solid form. This 
means that the solubility of the drug is likely to change several orders of magnitude 
during its release. 
 Compounds with very low solubility are inherently controlled, since their 
release over the time course of a dosage form in the GIT will be limited by dissolution 
of the drug. The lower limit for the solubility of a drug to be formulated in a sustained 
release system has been reported to be 0.1mg/mL (Fincher et al., 1968). Thus for 
slightly soluble drugs, diffusional systems will be poor choice, since the concentration 
in solution will be low.            
  For example Tetracycline has maximum solubility in the stomach and least     
solubility in the intestine where it is maximally absorbed. Other examples of drugs 
whose incorporation into sustained release systems are limited because of their poor 
aqueous solubility and slow dissolution rate are digoxin, warfarrin, griseofulvin and 
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salicylamide. Very soluble drugs are also good candidates for the sustained release 
dosage forms.  
3. Partition coefficient     
          The compounds with a relatively high partition coefficient are predominantly 
lipid soluble and easily penetrate membranes resulting high bioavailability. 
Compounds with very low partition coefficient will have difficulty in penetrating 
membranes resulting poor bioavailability. Furthermore partitioning effects apply 
equally to diffusion through polymer membranes. 
4. Drug Stability 
 The drugs, which are unstable in stomach, can be placed in a slowly soluble 
form and their release delayed until they reach the small intestine. However, such a 
strategy would be detrimental for drugs that either are unstable in the small intestine 
(or) undergo extensive gut wall metabolism, as pointed out in the decrease 
bioavailability of some anticholinergic drugs from controlled /sustained release 
formulation. In general the drugs, which are unstable in GIT environment poor 
candidates for oral sustained release forms. 
    5. Protein Binding  
       It is well known that many drugs bind to plasma proteins with a concomitant 
influence on the duration of drug action. Since blood proteins are mostly recirculated 
and not eliminated. Drug protein binding can serve as depot for drug producing a 
prolonged release profile, especially if a high degree of drug binding occurs. 
II. Biological Factors 
1. Biological Half-Life 
 Therapeutic compounds with half-life less than 8 hrs are excellent candidates 
for sustained release preparations. Drugs with very short half-life (less than 2 hrs) will 
require excessively large amounts of drug in each dosage unit to maintain controlled 
effects. Thus forcing the dosage form itself to become too large to be administered. 
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Compounds with relatively long half-lives, generally greater than 8 hrs are not used in 
the sustained release dosage forms, since their effect is already sustained and also GI 
transit time is 8-12 hrs (Jantzen et al., 1996)
.
 So the drugs, which have long -half life 
and short half- life, are poor candidates for sustained release dosage forms. 
Some examples of drug with half-lives of less than 2 hours are ampicillin, 
cephalexin, cloxacillin, furosemide, levodopa, penicillin G and propylthiouracil. 
Examples of those with half-lives of greater than 8 hours are dicumarol, diazepam, 
digitoxin, digoxin, guanethidine, phenytoin and warfarin. 
2. Absorption 
The characteristics of absorption of a drug can greatly affect its suitability as a 
sustained release product. Drugs which are absorbed by specialized transport process 
(carrier mediated) and drug absorption at special sites of the gastrointestinal tract 
(Absorption Window) are poor candidates for sustained release products. 
3. Metabolism 
  The metabolic conversion of a drug to another chemical form usually can be 
considered in the design of a sustained-release system for that drug. As long as the 
location, rate and extent of metabolism are known and the rate constant(s) for the 
process(es) are not too large, successful sustained-release products can be developed.          
 There are two factors associated with the metabolism of some drugs; however 
that present problems of their use in sustained-release systems. One is the ability of 
the drug to induce or inhibit enzyme synthesis; this may result in a fluctuating drug 
blood level with chronic dosing. The other is a fluctuating drug blood level due to 
intestinal (or other tissue) metabolism or through a hepatic first-pass effect. 
 Examples of drugs that are subject to intestinal metabolism upon oral dosing 
are hydralazine, salicylamide, nitroglycerine, isoproterenol, chlorpromazine and 
levodopa. Examples of drugs that undergo extensive first-pass hepatic metabolism are 
propoxyphene, nortriptyline, phenacetine, propranolol and lidocaine. 
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           Drugs that are significantly metabolized especially in the region of the small 
intestine can show decreased bioavailability from slower releasing dosage forms. This 
is due to saturation of intestinal wall enzyme systems. The drugs should not have 
intestinal first pass effect and should not induce (or) inhibit metabolism are good 
candidates for sustained release dosage forms. Various technologies used for 
controlled release drug delivery systems were given in Table 2 (Chien et al., 1990). 
Table 2. Technologies used for CRDDS  
S.NO. 
DESIGN OR TYPE OF THE 
SYSTEM 
RELEASE MECHANISM 
1 Dissolution Controlled CR systems 
 Encapsulation (including   Micro 
encapsulation) 
       - Barrier coating 
       - Embedment into a matrix of fatty 
materials)                                     
       - Repeat action coatings 
       - Coated plastic materials or 
hydrophilic materials 
Matrix Dissolution Control  
The dissolution of drug from system 
2 Diffusion Controlled CR systems 
 Reservoir Devices (Fatty polymer 
coated systems) 
Matrix Devices (Fatty polymer 
dispersed systems)       
The diffusion of the drug solution 
through a water - insoluble, permeable 
polymeric film 
 
3 Dissolution and Diffusion Controlled 
CR systems  
 Non disintegrating polymeric 
matrix 
 Hydrophilic matrices  
Diffusion of a drug solution through a 
porous matrix 
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4 Ion- Exchange Resin CR Systems Ion- Exchange between the resin - drug 
complex and  ions in the GI tract 
5 pH - Independent formulations 
 
Influenced by change in pH and ionic 
permeability of the membrane coating 
6 Osmotically Controlled CR systems 
They contain the buffering agents in a 
system which maintains constant pH 
throughout the GIT, so the drug release 
from the device is not affected by 
variable pH of GIT. Water entering by 
Osmosis dissolves the drug,  and the drug 
solution is forced out through a laser 
drilled orifice 
7 Altered - Density systems Diffusion from high - density pellets or 
from floating 
1.6. Monolithic Matrix System  
 In pharmaceutical CRDDS, matrix based systems are the most commonly used 
type of release controlling methodology owing to their simple manufacturing process. 
The preparation of a tablet with the matrix involves the direct compression of the 
blends of drug, release retardant and other additives, in which the drug is uniformly 
distribute throughout the matrix core of the release retardant. Alternatively, drug-
release retardant blends may be granulated to make the mix suitable for the 
preparation of tablets by wet granulation or beads (Colombo et al., 1995). 
 To characterize and define the matrix systems the following properties of the 
matrix are considered. 
1. Chemical nature of the support. 
2. The physical state of the drug. 
3. The matrix and alteration in volume as the function of the time. 
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4. The routes of administration. 
5. The release kinetics model (in accordance with Higuchi’s equation, these 
 system considered to release the drug as a function of square root of time).   
The classification of the matrix-based systems is based on the following criteria. 
 Matrix structure 
 Release kinetics 
 Controlled release properties (diffusion, erosion and swelling). 
 Chemical nature and the properties of the applied release retardant(s).  
Based on the chemical nature of the release retardant(s), the matrix systems are 
classified as given in Table 3. 
Table 3. Classification of Matrix Systems. 
Type of the Matrix System Mechanism 
Hydrophilic - Unlimited swelling delivery by diffusion 
- Limited swelling controlled delivery 
eg: Hydroxyethylcellulose, Hydroxypropylmethyl 
cellulose 
Inert - Inert in nature 
- Controlled delivery by diffusion 
eg: Ethylcellulose 
Lipidic - Delivery by diffusion & erosion 
eg: Carnauba wax. 
Biodegradable - Non lipidic nature 
- Controlled delivery by surface erosion 
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Resin Matrices - Drug release from drug-resin complex 
eg: Ion exchange resins 
 
1.7. Mechanism of Drug Release from Matrix Tablets 
 As shown in Figure 2, in erodible matrices, polymer erosion from the surface 
of the matrix determines the drug release; whilst in hydrophilic matrices, formation of 
the gel layer and its dynamics as a function of time determines the drug release. Gel 
layer thickness, which determines the diffusion path length of the drug, corresponds to 
the distance between the diffusion and erosion fronts. As the swelling process 
proceeds, the gel layer gradually becomes thicker, resulting in progressively slower 
drug-release rates; however, due to continuous hydration, polymer disentanglement 
occurs from the surface of the matrix, resulting in a gradually decreasing depletion 
zone and an increased dissolution rate. 
 
Fig.2. Schematic drug release from matrix diffusion controlled-release drug delivery 
systems with the drug homogenously dispersed in: (a) an erodible polymer matrix; 
and (b) a hydrophilic, sellable polymer matrix. 
1.8. Drug Release Kinetics -Model Fitting of the Dissolution Data  
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             Whenever a new solid dosage form is developed or produced, it is necessary 
to ensure that drug dissolution occurs in an appropriate manner. The pharmaceutical 
industry and the registration authorities do focus, nowadays, on drug dissolution 
studies. Drug dissolution from solid dosage forms has been described by kinetic 
models in which the dissolved amount of drug (Q) is a function of the test time, t or 
Q=f(t). Some analytical definitions of the Q(t) function are commonly used, such as 
zero order, first order, Hixson–Crowell, Higuchi, Korsmeyer–Peppas  models. (Mulye 
and Turco, 1995; Colombo et al., 1999; Kim et al., 1997; Manthena et al., 2004; Desai 
et al., 1996; Higuchi  et al., 1963).Different models expressing drug release kinetics 
were given in Table 4  
Zero order kinetics 
Q1 = Q0 +K0t 
 Where Q1 is the amount of drug dissolved in time t, Q0 is the initial amount of 
drug in the solution (most times, Q0=0) and K0 is the zero order release constant.  
ft = K0 t 
 Where ft = 1-(Wt/W0) and ft represents the fraction of drug dissolved in time t 
and K0 the apparent dissolution rate constant or zero order release constant. In this 
way, a graphic of the drug-dissolved fraction versus time will be linear if the 
previously established conditions were fulfilled. 
Use: This relation can be used to describe the drug dissolution of several types of 
modified release pharmaceutical dosage forms, as in the case of some transdermal 
systems, as well as matrix tablets with low soluble drugs, coated forms, osmotic 
systems, etc. The pharmaceutical dosage forms following this profile release the same 
amount of drug by unit of time and it is the ideal method of drug release in order to 
achieve a pharmacological prolonged action.  
First order kinetics 
Kinetic equation for the first order release is as follows 
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Log Qt = log Q0 + K1t/2.303 
 Where Qt is the amount of drug released in time t, Q0 is the initial amount of 
drug in the solution and K1 is the first order release constant. In this way a graphic of 
the decimal logarithm of the released amount of drug versus time will be linear.  
 
 The pharmaceutical dosage forms following this dissolution profile, such as 
those containing water-soluble drugs in porous matrices, release the drug in a way that 
is proportional to the amount of drug remaining in its interior, in such way, that the 
amount of drug released by unit of time diminishes. 
Higuchi model    
ft = KH t
1/2 
 Where KH is the Higuchi dissolution constant treated sometimes in a different 
manner by different authors and theories. Higuchi describes drug release as a 
diffusion process based in the Fick’s law, square root time dependent. This relation 
can be used to describe the drug dissolution from several types of modified release 
pharmaceutical dosage forms, as in the case of some transdermal systems and matrix 
tablets with water-soluble drugs. 
Hixson–Crowell model 
 Hixson and Crowell (1931) recognizing that the particle regular area is 
proportional to the cubic root of its volume derived an equation that can be described 
in the following manner 
W0 
1/3
-Wt 
1/3
 = Kst 
 Where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt 
is the remaining amount of drug in the pharmaceutical dosage form at time t and Ks is 
a constant incorporating the surface–volume relation. This expression applies to 
pharmaceutical dosage form such as tablets, where the dissolution occurs in planes 
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that are parallel to the drug surface if the tablet dimensions diminish proportionally, in 
such a manner that the initial geometrical form keeps constant all the time.           
           A graphic of the cubic root of the unreleased fraction of drug versus time will 
be linear if the equilibrium conditions are not reached and if the geometrical shape of 
the pharmaceutical dosage form diminishes proportionally over time. This model has 
been used to describe the release profile keeping in mind the diminishing surface of 
the drug particles during the dissolution. 
Mechanism of Drug Release     
 To find out the drug release mechanism due to swelling (upon hydration) 
along with gradual erosion of the matrix, first 60% drug release data can be fitted in 
Korsmeyer–Peppas model which is often used to describe the drug release behavior 
from polymeric systems when the mechanism is not well-known or when more than 
one type of release phenomena is involved (Korsmeyer et al., 1983). 
                                          Log (Mt / M∞) = Log KKP + n Log t           
 Where, Mt is the amount of drug release at time t, M∞ is the amount of drug 
release after infinite time, KKP is a release rate constant incorporating structural and 
geometrical characteristics of the tablet, and n is the release exponent indicative of the 
mechanism of drug release.  
Table 4.  Drug Release Kinetics 
Kinetic 
Model 
Relation Systems Following the Model 
First order 
 
ln Qt = ln Qo + Kt 
(release is proportional to amount of drug 
remaining) 
Water-soluble drugs in porous 
matrix 
 
Zero order 
 
ft = Kot 
(independent of drug concentration) 
Transdermal systems 
Osmotic systems 
Higuchi 
 
ft = KHt
1/2 
(proportional to square root of time) 
Matrix formulations 
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Hixson-
Crowell 
Wo 
1/3
 – Wt 
1/3
 = Kst Erodible isometric matrices 
ft = fraction of dose release at time ‘t’;  
KH, Ko, and Ks = release rate constants characteristic to respective models;  
Qo = the drug amounts remaining to be released at zero hour;  
Qt = the drug amounts remaining to be released at time ‘t’;  
Wo = initial amount of drug present in the matrix;  
Wt = amount of drug released at time ‘t’. 
                                   
1.9. Introduction to Hypertension and Timolol Maleate 
 Blood pressure is the force of blood pushing against blood vessel walls. The 
heart pumps blood into the arteries (blood vessels), which carry the blood throughout 
the body. High blood pressure, also called hypertension, is dangerous because it 
makes the heart work harder to pump blood to the body and it contributes to 
hardening of the arteries or atherosclerosis and the development of heart failure. 
 Hypertension, also referred to as high blood pressure, HTN or HPN, is a 
medical condition in which the blood pressure is chronically elevated.  
 There are several categories of blood pressure, including 
 Normal: 120/80 mm of Hg 
 Prehypertension: 120-139/80-89 mm of Hg 
 Stage 1 hypertension: 140-159/90-99 mm of Hg 
 Stage 2 hypertension: 160 and above/100 and above  
 Hypertension can be classified either essential (primary) or secondary.  
 Essential hypertension indicates that no specific medical cause can be found to 
explain a patient's condition. Secondary hypertension indicates that the high blood 
pressure is a result of (i.e., secondary to) another condition, such as kidney disease or 
tumours.  
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The mechanisms and causes of hypertension 
The direct mechanisms causing hypertension is one or more of these factors 
 An increased tension in the blood vessel walls. 
 An increased blood volume caused by elevated levels of salt and lipids in the 
blood holding back water. 
 Hardened and inelastic blood vessels caused by arteriosclerosis. 
 The primary causes behind these mechanisms are not fully understood, but 
these factors contribute to causing hypertension 
 A high consume of salt 
 A high fat consume. 
 Stress at work and in the daily life. 
 Smoking. 
 Over-weight 
 Lack of exercise. 
 Kidney failure. 
Lifestyle measures to prevent and treat hypertension 
 Lifestyle measures shall always be a component of the hypertension treatment. 
Sometimes such measures are enough to cure the condition. Those measures are 
 Reducing salt consume. 
 Reduction of fat consume, and especially of saturated fat consume. 
 Weight reduction. 
 Relaxing and stress reduction techniques, for example meditation and 
autogenic training. 
 Regular exercise. 
Special food types that reduce the blood pressure 
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Research projects suggest that the following food types reduce blood pressure. 
  Fish oil and fat fish. The working substances seem to be the omega-3 
unsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA). The effect from fish oil seems to cease when the fish oil supplements 
are stopped. 
 Olive oil, especially olive oil of the quality extra virgin. 
Natural supplements to help against hypertension 
  Natural supplements to treat hypertension exist. These supplements reduce 
blood pressure by lowering the cholesterol and lipid content in the blood, by 
preventing oxidation of tissue components by free radicals, and by helping damaged 
blood vessels to heal. Examples of ingredients having these effects are vitamin B3, 
inositol, turmenic extract and gum guggul extract.  
          They may also contain Ingredients giving a direct anti-hypertensive effect, like 
potassium, magnesium, calcium, vitamin C and fatty acids from marine sources. 
Medical treatment of hypertension  
           When lifestyle measures and supplements are not enough to cure the condition, 
medical treatment must be applied. Many different types of drugs are used, alone or in 
combination with other drugs, to treat high blood pressure. The major categories are 
 Angiotensin-converting Enzyme (ACE) Inhibitors: ACE inhibitors work by 
preventing a chemical in the blood, angiotensin I, from being converted into a 
substance that increases salt and water retention in the body. These drugs also 
make blood vessels relax, which further reduces blood pressure.  
 Angiotensin II Receptor Antagonists: These drugs act at a later step in the 
same process that ACE inhibitors affect. Like ACE inhibitors, they lower 
blood pressure by relaxing blood vessels.  
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 Beta blockers: Beta blockers affect the body's response to certain nerve 
impulses. This, in turn, decreases the force and rate of the heart's contractions, 
which lowers blood pressure.  
 Blood Vessel Dilators (Vasodilators): These drugs lower blood pressure by 
relaxing muscles in the blood vessel walls.  
 Calcium Channel Blockers: Drugs in this group slow the movement of 
calcium into the cells of blood vessels. This relaxes the blood vessels and 
lowers blood pressure.  
 Diuretics: These drugs control blood pressure by eliminating excess salt and 
water from the body.  
 Nerve Blockers: These drugs control nerve impulses along certain nerve 
pathways. This allows blood vessels to relax and lowers blood pressure.  
Beta blockers 
           Beta blockers differ by which receptors are blocked.  
           First generation beta blockers such as propranolol (Inderal, InnoPran), nadolol 
(Corgard), timolol maleate  (Blocadren), penbutolol sulfate (Levatol), sotalol 
hydrochloride (Betapace), and pindolol (Visken) are non-selective in nature, meaning 
that they block both beta1 (β1) and beta2 (β2) receptors and will subsequently affect the 
heart, kidneys, lungs, gastrointestinal tract, liver, uterus, vascular smooth muscle, and 
skeletal muscle and as an effect, could cause reduced cardiac output, reduced renal 
output amongst other actions.  
          Second generation beta blockers such as metoprolol (Lopressor, Toprol XL), 
acebutolol hydrochloride (Sectral), bisoprolol fumarate (Zebeta), esmolol 
hydrochloride (Brevibloc), betaxolol hydrochloride (Kerlone), and acebutolol 
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hydrochloride (Sectral) are selective, as they block only β1 receptors and as such will 
affect mostly the heart and cause reduced cardiac output.     
           Beta blockers such as pindolol (Visken), penbutolol sulfate (Levatol), and 
acebutolol hydrochloride (Sectral) differ from other beta blockers as they possess 
intrinsic sympathomimetic activity (ISA), which means they mimic the effects of 
epinephrine and norepinephrine and can cause an increase in blood pressure and heart 
rate. ISA's have smaller effects in reducing resting cardiac output and resting heart 
rate, in comparison to drugs that do not possess ISA. 
           Beta blocker such as propranolol (Inderal, InnoPran), acebutolol hydrochloride 
(Sectral), and betaxolol hydrochloride (Kerlone) possess a quinidine-like or 
anesthetic-like membrane action, which affects cardiac action potential (electrical 
impulses within the heart that cause contractions).   
            Beta blockers such as labetalol hydrochloride (Trandate, Normodyne) and 
carvedilol (Coreg)  have both β- and α1-adrenergic receptors. Blocking the α1-
adrenergic receptors in addition to the β blocker lowers blood pressure which 
provides additional vasodilatory action of the arteries.  
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REVIEW OF LITERATURE 
2.1. Matrix Formers  
 Avachat et al., (2007) have studied the effect of different concentrations of 
hydroxypropylmethylcellulose (HPMC K100CR) on the simultaneous release of both 
diclofenac sodium (DS) and chondroitin sulphate (CS). They revealed that HPMC K 
100CR at a concentration of 40% of the dosage form weight was able to control the 
simultaneous release of both DS and CS for 9hours. 
Krishnan et al., (2007) have prepared sustained release tablets of theophylline 
using tamarind seed polysaccharide as release retardant. The release of drug from 
these matrices was found to occur by swelling controlled mechanism obeying first 
order kinetics. 
Nair et al., (2007) have made an attempt to formulate a controlled-release 
matrix tablet formulation for alfuzosin hydrochloride by using low viscous 
hydroxypropylmethylcellulose (HPMC K-100 and HPMC 15cps) and its comparison 
with marketed product. Drug release from the matrix tablets was carried out for 12 hr 
and showed that the release rate was not highly significant with different ratios of 
HPMC K-100 and HPMC15cps. They concluded that the use of low viscous 
hydrophilic polymer of different grades (HPMC K-100 and HPMC 15cps) can control 
the alfuzosin release for a period of 12 hr and were comparable to the marketed 
product. 
Raslan et al., (2006) have studied the effect of HPMC (hydrophilic) and 
glyceryl behenate (hydrophobic) polymers on controlled release of anhydrous 
theophylline matrix tablets and studied invitro release characteristics and kinetics of 
prepared formulations for explaining the release pattern from matrix tablets. 
Atul Kuksal et al., (2006) have prepared extended-release matrix tablets of 
zidovudine using hydrophilic eudragit RLPO and RSPO alone and their combination 
with hydrophobic ethylcellulose (EC). The in-vitro drug release study revealed that 
either eudragit preparation was able to sustain the drug release for 6h.Combining 
eudragit with EC sustained the drug release for 12 h. 
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Hamid et al., (2006) have formulated & evaluated a once-daily tablet of 
cefpodoxime using HPMC K4M. They revealed that 35% w/w of HPMC controlled 
the cefpodoxime proxetil release effectively for 24hours. 
Jaleh et al., (2006) have developed sustained-release matrix tablets of highly 
water-soluble tramadol HCl using natural gums like xanthan gum and guar gum alone 
or in combination with HPMC. They concluded that guar gum alnoe cannot 
efficiently control drug release, and xanthan gum has higher drug retarding ability 
than guar gum. The combination of each natural gum with HPMC leads to a greater 
retarding effect compared with a mixture of two natural gums.  
Saleh et al., (2005) have studied the effect of different viscosity grades LM 
(30% w/w), MM (40% w/w), HM (50% w/w) of guar gum on the drug release pattern 
of water-soluble diltiazem hydrochloride. They found that high molecular weight 
(50% w/w) grade guar gum was able to control the drug release patterns in-vitro and 
in-vivo. 
Vidhyadhara et al., (2004) have revealed that the HPMC K4M along with 
electrolytes can be used as aids to controlled delivery in the formulation of water 
soluble drugs like propranolol HCl from tablet matrix. 
Jaber et al., (2004) have shown that 15% w/w of carbopol or sodium 
carboxymethylcellulose or 35% w/w of HPMC K100M can be useful to sustain the 
release of lithium carbonate from matrix tablet over 8 hours. 
Sandip et al., (2003) have studied the effect of concentration of hydrophilic 
(HPMC) and hydrophobic (hydrogenated castor oil [HCO], EC) on the release rate of 
tramadol HCl. Tablets prepared by combination of hydrophilic and hydrophobic 
polymers failed to produce the drug release beyond 12 h. HCO matrix tablets were 
found to be best suited for modulating the delivery the highly water-soluble drug, 
tramadol HCl. 
Selim et al., (2003) have done the comparative evaluation of plastic, 
hydrophobic and hydrophilic polymers as matrices for controlled-release drug 
delivery. They revealed that the drug release from plastic and hydrophobic matrix was 
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less than hydrophilic polymer. Again, the release pattern of drug from hydrophilic 
matrices was closer to zero-order kinetics than that from other classes of matrices. 
Maggi et al., (2000) have compared the performance of polyethylene oxide 
(PEO) and HPMC polymers when employed in the geomatrix technology. They have 
shown that slower release rates can be obtained from the plain matrices containing 
HPMC compared to PEO. 
Nath et al., (1999) have discussed the use of combination of aliphatic alcohol 
(cetyl alcohol) and methylcellulose as a sustained release matrix using theophylline as 
a model drug. They have shown that 30% w/w total matrix component gave extended 
release of theophylline for more than 8hours. 
Pillay et al., (1999) have studied the interaction between drug and 
electrolyte(s) to control the release of highly water soluble diltiazem hydrochloride 
from oral hydrophilic monolithic systems. They have used hydrophilic polymers like 
HPMC and PEO. Electrolytes such as sodium bicarbonate or pentasodium 
tripolyphosphate were used to modulate intragel pH dynamics, swelling kinetics, and 
gel properties. They concluded that the dynamics of swelling and gel formation in the 
presence of ionizable species within hydrophilic matrices provide an attractive 
alternative for zero-order drug delivery from a simple monolithic system. 
Bhalla et al., (1998) have prepared controlled release tablets of 
carbamazepine using HPMC and EC as release retardants and performed in-vitro & 
in-vivo studies. They found that EC based formulation was found to be more stable 
and compared well with the innovator’s product. 
Kim et al., (1997) have developed a new ternary polymeric matrix system 
using pectin, HPMC and gelatin to deliver a highly soluble drug like diltiazem HCl 
over long periods of time. They mentioned that this system offers a number of 
advantages over existing systems, including ease of manufacturing and of release 
modulation, as well as reproducibility of release profiles. 
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2.2. Formulation and Process Variables 
Hiremath et al., (2008) have formulated hydrophilic controlled release matrix 
tablets of rifampicin, a poorly soluble drug, using hydroxypropyl methylcellulose 
(HPMC) polymer (low, medium, and high viscosity) by direct compression method. 
Influence of formulation variables and process parameters such as drug:HPMC ratio, 
viscosity grade of HPMC, drug particle size, and compression force on the 
formulation characters and drug release has been studied. Their results indicated that 
the release rate of the drug and the mechanism of release from the HPMC matrices are 
mainly controlled by the drug:HPMC ratio and viscosity grade of the HPMC. In 
general, decrease in the drug particle size decreased the drug release. Lower viscosity 
HPMC polymer was found to be more sensitive to the effect of compression force 
than the higher viscosity. 
Ravi et al., (2008) have designed oral controlled release (CR) matrix tablets of 
zidovudine (AZT) using HPMC, EC and cabopol-971P (CP) and studied the effect of 
various formulation factors on in vitro drug release. . Release rate decreased with 
increase in polymer proportion and compression force. The release rate was lesser in 
formulations prepared using CP (20%) as compared to HPMC (20%) as compared to 
EC (20%). No significant difference was observed in the effect of pH of dissolution 
media on drug release from formulations prepared using HPMC or EC, but significant 
difference was observed in CP based formulations. Decrease in agitation speed from 
100 to 50 rpm decreased release rate from HPMC and CP formulations but no 
significant difference was observed in EC formulations. Mechanism of release was 
found to be dependent predominantly on diffusion of drug through the matrix than 
polymer relaxation incase of HPMC and EC formulations, while polymer relaxation 
had a dominating influence on drug release than diffusion incase of CP formulations. 
Designed CR tablets have shown an initial release of 17-25% in first hour and 
extending the release up to 16-20 hours. 
           Roberts et al., (2007) have studied the release profiles of aspirin from 
hypromellose matrices in hydro-ethanolic media. Percent aspirin released increased 
with increasing levels of ethanol in the dissolution media, correlating with the drug's 
solubility, however, dose dumping of aspirin did not occur. An initial rapid release 
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was observed in media comprising 40% ethanol. Release in these conditions was 
considered to be both erosion and diffusion-mediated, in contrast to the release in 0, 
10, 20 and 30% ethanol media, where erosion-controlled release dominated. Image 
analysis of matrix swelling indicated a slower initial interaction between ethanol and 
hypromellose accounting for the initial rapid release. Cloud point studies suggested 
that ethanol retarded hydration of the polymer.  
Sinju et al., (2004) have described the effects of temperature and humidity on 
tablets containing kollidon
®
 SR using diphenhydramine HCl as a model drug. 
Exposure of tablets to accelerated stability condition (40°C/75%RH) in an open dish 
resulted in rapid increases in tablet hardness, accompanied by step-wise decreases in 
dissolution rate.  But exposure to 25°C/60%RH similarly resulted in increases in 
tablet hardness, although with minimal impact on dissolution. Exposure of kollidon
®
 
SR tablets to the aqueous coating process indeed resulted in noticeable changes in 
both hardness and dissolution. Application of the opadry solution appears to affect 
tablet behavior to a lesser degree, compared to water, most likely due to protection via 
formed barrier film. Therefore the authors concluded that attention needs to be paid to 
the extreme sensitivity of kollidon
®
 SR matrix tablets to temperature and moisture 
during product development.  
Silvina et al., (2002) have developed HPMC matrix tablets of diclofenac 
sodium, evaluated the relationship and influence of different content levels of 
microcrystalline cellulose (MCC), starch, and lactose, in order to achieve a zero-order 
release. They found that each of these compounds was capable of interacting to some 
extent with each other to control drug release. 
Paul et al., (1995) have investigated the effects of lubricant magnesium 
stearate at different concentrations, mixing shear rate, and mixing times on the tablet 
properties and drug dissolution from controlled release matrix tablets containing 
HPMC K4M. Diphenhydramine HCl and hydrochlorothiazide were chosen as the 
model drugs. Spray –dried hydrous lactose (Fast-Flo Lactose) and anhydrous dibasic 
calcium phosphate (A-TAB) were chosen as the model fillers.  Tablets containing A-
TAB, which compacts via a brittle fracture mechanism, were harder and had 
significantly better friability patterns than those prepared using Fast Flo Lactose. The 
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compaction of Fast Flo Lactose appears to be a combination of brittle fracture and 
plastic deformation. Mixes containing lower levels of lubricant (0.2%) generated 
tablets that had higher crushing strengths than those with higher lubricant levels 
(2.0%). Drug release was impacted to the greatest extent by the solubility of the drug 
and excipients/filler but was only slightly affected by the level of magnesium stearate 
and duration of mixing. 
 Chapter 3 
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 RESEARCH ENVISAGED 
3.1. Objective 
 The present work is aimed at preparing and evaluating sustained-release (SR) 
matrix  tablets of timolol maleate (TM) using different polymers  
 To study the effect of nature (hydrophilic, hydrophobic and plastic) of the 
polymer and drug:polymer ratio (1:0.5, 1:1, 1:1.5, and 1:2) on the rate of drug 
release. 
 To study the effect of different diluents (Microcrystalline cellulose (MCC),   
lactose) on drug release rate.  
 To study the effect of method of preparation of tablets (wet granulation and 
direct compression) on the rate of drug release. 
3.2. Scope of Work 
           Timolol maleate is a non-selective beta-adrenergic receptor blocker used in the 
treatment of essential hypertension, glaucoma, migraine, and for prophylaxis after 
myocardial infraction. It is rapidly and nearly completely (about 90%) absorbed from 
the gastrointestinal tract (GIT) following oral ingestion, showing 60% bioavailability. 
Detectable plasma levels occur within one-half hour and peak plasma levels occur in 
about 1-2 hours. A plasma half-life is 4 hours. In the treatment of hypertension the 
usual initial dosage is 10 mg twice a day, whether used alone or added to diuretic 
therapy. Dosage may be increased or decreased depending on heart rate and blood 
pressure response. The usual total maintenance dosage is 20-40 mg per day. Increases 
in dosage to a maximum of 60 mg per day divided into two doses may be necessary 
(Thomson et al., 2006). 
             Although conventional tablets of timolol maleate available in the market 
commercially, no study has been done so far for preparing the timolol maleate 
sustained-release tablets. To improve the oral bioavailability and to reduce the dose 
dependent toxicity there is a need for the development of sustained-release 
formulations. Many patent technologies also indicated that timolol maleate is suitable 
for the sustained-release (Gregory et al., 2004; Mandana et al., 2000).         
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The most commonly used method of modulating the drug release is to include 
it in a matrix system (Salsa et al., 1997).An effort was therefore made to develop 
simple and effective sustained-release timolol maleate tablets using a polymer matrix 
system. The drug is freely soluble in water and hence judicious selection of matrix 
formers is essential for achieving constant release. HPMC is the most commonly and 
successfully used hydrophilic retarding agent for the preparation of oral controlled 
drug delivery systems (Colombo et al., 1993).Upon contact with the gastrointestinal 
fluid, HPMC swells, gels, and finally dissolves slowly (Siepmann et al., 1999). The 
gel becomes a viscous layer acting as a protective barrier to both the influx of water 
and the efflux of the drug in solution (Colombo et al., 2000; Kiil et al., 2003). As the 
proportion of the polymer in the formulation increases, the gel formed is more likely 
to diminish the diffusion of the drug and delay the erosion of the matrix (Ford et al., 
1985). The dissolution can be either disentanglement or diffusion controlled 
depending on the molecular weight and thickness of the diffusion boundary layer. The 
rate of polymer swelling and dissolution as well as the corresponding rate of drug 
release are found to increase with either higher levels of drug loading or with use of 
lower viscosity grades of HPMC (Narasimhan et al.,1997). However, the use of 
hydrophilic matrix former alone for sustaining drug release for highly water soluble 
drugs is restricted due to rapid diffusion of the dissolved drug through the hydrophilic 
gel network. For such drugs it is necessary to include hydrophobic polymers in the 
matrix system (Liu et al., 2001).    
           Hence, in the present study, an attempt has been made to develop the 
sustained-release matrix tablets of TM using hydrophilic HPMC K100M CR in 
combination with hydrophobic ethylcellulose, and the sustained pattern of timolol 
maleate was evaluated by in-vitro drug release for 12 hours. The drug release data 
were plotted using various kinetic equations (zero-order, first-order, Higuchi’s 
kinetics, Korsmeyer’s equation, and Hixson-Crowell cube root law) to evaluate the 
drug release mechanism and kinetics. In-vivo drug release, biopharmaceutical 
evaluation, and in-vitro/in-vivo correlations were beyond the scope of this study and 
will be considered in future work. 
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3.3. Plan of The Work 
To achieve the objectives of the work, the following work was planned and 
undertaken: 
1) Drug Selection 
2) Literature Survey 
3) Preformulation Study 
Compatability evaluation was carried out between drug and polymers in 
physical observation and by using infrared spectral study. 
       4) Construction of the calibration curve for timolol maleate in 0.1N HCl and 6.8 
pH phosphate buffer. 
       5) Calculation of the dose and to construct theoretical release profile of timolol 
maleate from sustained –release formulations. 
        6) Preparation of SR formulations of TM using Microcrystalline cellulose as a 
diluent, following polymers at different concentrations and combinations by wet 
granulation technique or direct compression. 
             HPMC K15M 
             Polyethylene oxide 
             HPMC K100M CR 
             Ethylcellulose  
             Kollidon-SR  
     7) Selection of the best batch of tablets based on the in-vitro release studies and 
similarity factor analysis. 
       8) By using the composition of selected batch, tablets will be prepared by direct 
compression method and will be evaluated. 
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        9)To perform swelling and erosion studies, FTIR studies, and stability studies for 
the optimized formulation. 
       10) The following evaluation parameters were studied based on laboratory 
experiments. 
A. Evaluation of blends     
A) Angle of repose 
B) Apparent bulk density 
C) Tapped bulk density 
D) Percent compressibility 
E) Hausener’s ratio 
      B. Evaluation of tablets 
   a)     Tablet description 
   b)     Tablet thickness and diameter 
   c)     Hardness 
   d)     Friability 
   e)     Weight variation 
  f)      Content uniformity of active ingredient 
  g)      In vitro dissolution study 
  h)     The results of drug release will be studied for zero order of release, Higuchi’s 
classical diffusion equation and kosmeyer’s peppa’s equation. 
  i)       Similarity Factor (f2) Analysis 
j)      Swelling and erosion studies    
k)     FTIR Studies    
  l)      Optimization of the formulation 
  m)      Accelerated stability study of optimized formulation. 
 Chapter 4 
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Drug Profile  
TIMOLOL MALEATE 
                 Timolol maleate is a nonselective beta-adrenergic receptor blocking agent. It 
possesses an asymmetric carbon atom in its structure and is provided as the levo isomer. 
4.1. Description 
Nomenclature 
 Generic Name: Timolol Maleate 
 Chemical Name: (S)-1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-     
thiadiazol-3-yl]oxy]-2-propanol (Z)-2-butenedioate (1:1) salt. 
 Trade Names: Blocadren, Betim, Timoster, Betimol, Novo-Timol, Timoptic. 
 Formula 
 Empirical Formula: C13H24N4O3S•C4H4O4 
 Structural Formula 
    
 
Physical and Chemical Properties 
 Molecular weight     - 432.50. 
 Color     - White  
 Nature                       -       Crystalline powder 
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 Odour                        - Odourless 
 Melting point - 201.5-202.5 °C 
 Solubility       -   Freely soluble in water; soluble in ethanol and methanol. Sparingly 
soluble in chloroform, practically insoluble in ether and cyclohexane. 
 pKa                          -         3.9 
4.2. Pharmacokinetics 
              Timolol maleate is rapidly and nearly completely absorbed (about 90%) following 
oral ingestion. Detectable plasma levels of timolol occur within one-half hour and peak 
plasma levels occur in about one to two hours. The drug half-life in plasma is 
approximately 4 hours and this is essentially unchanged in patients with moderate renal 
insufficiency. The absolute bioavailability after oral administration has been reported to be 
approximately 60%. Timolol is not extensively bound to plasma proteins; i.e., < 10% by 
equilibrium dialysis and approximately 60% by ultrafiltration. It is extensively (80%) 
metabolized in liver via the cytochrome P450 2D6 isoenzyme, the metabolites being 
excreted in urine together with some unchanged timolol. Plasma levels following oral 
administration are about half those following intravenous administration indicating 
approximately 50% first pass metabolism. It crosses the placenta and appears in breast 
milk. 
4.3. Pharmacology 
i)   Indications and Dosage  
 Hypertension: The usual initial dosage of timolol maleate is 10 mg twice a day, 
whether used alone or added to diuretic therapy. Dosage may be increased or decreased 
depending on heart rate and blood pressure response. The usual total maintenance 
dosage is 20 to 40 mg per day. Increases in dosage to a maximum of 60 mg per day 
divided into two doses may be necessary. There should be an interval of at least 7 days 
between increases in dosages.  
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Timolol maleate tablets may be used with a thiazide diuretic or with other 
antihypertensive agents. Patients should be observed carefully during initiation of such 
concomitant therapy. 
 Myocardial Infarction: The recommended dosage for long-term prophylactic use 
in patients who have survived the acute phase of a myocardial infarction is 10 mg 
given twice daily. 
 Migraine: The usual initial dosage of timolol maleate is 10 mg twice a day. During 
maintenance therapy the 20 mg daily dosage may be administered as a single dose. 
Total daily dosage may be increased to a maximum of 30 mg, given in divided doses, 
or decreased to 10 mg once per day, depending on clinical response and tolerability. If 
a satisfactory response is not obtained after 6 to 8 weeks use of the maximum daily 
dosage, therapy with timolol should be discontinued. 
 Glaucoma: Ophthalmic Solution is indicated in the treatment of elevated 
intraocular pressure in patients with ocular hypertension or open-angle glaucoma. 
ii) Contraindications 
    Timolol maleate is contraindicated in patients with bronchial asthma or with a 
history of bronchial asthma, or severe chronic obstructive pulmonary disease sinus 
bradycardia; second- and third-degree atrioventricular block; overt cardiac failure; 
cardiogenic shock; hypersensitivity to this product. 
iii) Mechanism of Action 
   Mechanism of action like propranolol and nadolol, timolol competes with 
adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic 
receptors in the heart and vascular smooth muscle and beta(2)-receptors in the bronchial 
and vascular smooth muscle. Beta(1)-receptor blockade results in a decrease in resting and 
exercise heart rate and cardiac output, a decrease in both systolic and diastolic blood 
pressure, and, possibly, a reduction in reflex orthostatic hypotension. Beta (2)-blockade 
results in an increase in peripheral vascular resistance. The exact mechanism whereby 
timolol reduces ocular pressure is still not known. The most likely action is by decreasing 
the secretion of aqueous humor. 
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iv) Drug Interaction : 
                  Timolol has some interactions with the drugs like catecholamine-depleting 
drugs such as reserpine, non-steroidal anti-inflammatory drugs, calcium antagonists, 
digitalis, quinidine and clonidine. 
v) Adverse Effects 
        Fatigue, bradycardia, nausea, dizziness, bronchial spasm, pruritis. But it is    
usually well tolerated in properly selected patients. Most adverse effects have been mild & 
transient. 
VI) Precautions 
        Timolol maleate has been detected in human milk. Because of the potential for 
serious adverse reactions from timolol in nursing infants, a decision should be made 
whether to discontinue nursing or to discontinue the drug, taking into account the 
importance of the drug to the mother. Safety and effectiveness in pediatric patients have 
not been established. 
VII) Toxicity 
LD50=1190 mg/kg (oral, mice) 
        LD50=900 mg/kg (oral, rat). 
4.4.  Pharmacodynamics 
         Timolol maleate is a beta1 and beta2 (nonselective) adrenergic receptor blocking 
agent that does not have significant intrinsic sympathomimetic, direct myocardial 
depressant, or local anesthetic activity. Clinical pharmacology studies have confirmed the 
beta-adrenergic blocking activity as shown by (1) changes in resting heart rate and 
response of heart rate to changes in posture; (2) inhibition of isoproterenol-induced 
tachycardia; (3) alteration of the response to the valsalva maneuver and amyl nitrite 
administration; and (4) reduction of heart rate and blood pressure changes on exercise. 
Timolol decreases the positive chronotropic, positive inotropic, bronchodilator, and 
vasodilator responses caused by beta-adrenergic receptor agonists. 
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           Clinical studies indicate that timolol maleate at a dosage of 20 to 60 mg/day 
reduces blood pressure without causing postural hypotension in most patients with 
essential hypertension. Administration of timolol to patients with hypertension results 
initially in a decrease in cardiac output, little immediate change in blood pressure, and an 
increase in calculated peripheral resistance. With continued administration of timolol, 
blood pressure decreases within a few days, cardiac output usually remains reduced, and 
peripheral resistance falls toward pretreatment levels. Plasma volume may decrease or 
remain unchanged during therapy with timolol. In the majority of patients with 
hypertension timolol also decreases plasma renin activity. Dosage adjustment to achieve 
optimal antihypertensive effect may require a few weeks. When therapy with timolol is 
discontinued, the blood pressure tends to return to pretreatment levels gradually. In most 
patients the antihypertensive activity of timolol is maintained with long-term therapy and 
is well tolerated. 
4.5. Method of analysis 
 Spectroscopy like-IR, NMR, Mass and UV-Visible Spectroscopy. 
 Thin Layer Chromatography 
 High Performance Liquid Chromatography 
4.6. Storage 
Tablets should be stored at 20° to 25°C (68° to 77°F), protected from light. 
Dispense in a well-closed, light-resistant container. 
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4.7. Official preparations  
 IP, 1996:   Timolol Maleate eye drops. 
   Timolol Maleate tablets. 
 BP, 1993: Timolol eye drops, Timolol tablets. 
 USP/NF, 2004: Timolol Maleate & Hydrochlorthiazide tablets.     
                                      Timolol Maleate opthalmic solution. 
                                Timolol Maleate tablets. 
4.8. Proprietary Formulations: 
    Opthalmic solutions : Timol  (India)  
                                                            Timoptic 0.25%, 0.5% (USA) 
 Tablets :     Timostar 10mg, 20mg (Mankind Pharma, India) 
                                          Blocadren  5 mg, 10 mg, 20 mg (Merck & Co., USA) 
                                      Betim (UK) 
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5 .POLYMER AND EXCIPIENT PROFILE  
                    The following are the different polymers and excipients used in this work 
(Raymond et al., 2003) 
5.1. Hypromellose 
Hypromellose is a partly O-methylated and O-(2- hydroxypropylated) cellulose. 
Synonyms          :     Benecel MHPC; Hydroxypropylmethylcellulose (HPMC); 
                                           Methocel; Metolose; Tylopur. 
Description      : Odorless and tasteless, white or creamy-white fibrous or granular powder. 
Grades    :        Methocel K100 Premium LVEP, Methocel K4M, K15M,K100M,Metolose   
                   60SH, 65SH, 90SH. 
Stability     :      Stable material, although it is hygroscopic after drying. 
Acidity/alkalinity         :          pH = 5.5–8.0 for a 1% w/w aqueous solution 
Density (true)               :          1.326 g/cm
3
. 
Melting point               :         Browns at 190–200°C; chars at 225–230°C. Glass     
transition  temperature is 170–180°C. 
Viscosity                      :         Ranges from 3-100000 mPa s. 
                                    Methocel K100M (100000 mPa s),  
                                    Methocel  K15M (15000 mPa s), 
                                    Methocel K4M (4000 mPa s). 
Safety                           :       Non-toxic and non-irritant material, although excessive 
                                              oral consumption may have a laxative effect. 
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Uses                             :       As a tablet binder (2% - 5% w/w), 
                                             Matrix former (10% - 80% w/w), 
                                             Thickening agent (0.45% - 1% w/w), 
                                          It is also used as an emulsifier, suspending agent, and          
stabilizing agent in topical gels and ointments. 
5.2. Polyethylene Oxide 
Polyethylene oxide as a nonionic homopolymer of ethylene oxide, represented by 
the formula (CH2CH2O)n, where n represents the average number of oxyethylene groups. 
It may contain up to 3% of silicon dioxide.  
Synonyms                         :     Polyox;  Polyoxirane;  Polyoxyethylene. 
Description                      :     White to off-white, free-flowing powder, slightly ammonical 
odour. 
Functional Category       :     Mucoadhesive; Tablet binder; Thickening agent 
Grades                             :  WSR N-10, WSR N-80, WSR N-750, WSR N-3000, WSR     
                                     205, WSR 1105, SR N-60K, WSR 301, WSR coagulant, WSR 303. 
Solubility                    :    Soluble in water and a number of common organic solvents such 
as acetonitrile, chloroform, and methylene chloride. It is insoluble in aliphatic 
hydrocarbons, ethylene glycol, and most alcohols. 
Angle of Repose             :       34° 
Density (true)                :       1.3 g/cm
3
    
Melting Point                :       65–70°C 
Storage Conditions    :    Store in tightly sealed containers in a cool, dry place. Avoid 
exposure to high temperatures since this can result in reduction in viscosity. 
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Safety                     :       Low level of toxicity regardless of the route of administration. 
The resins are neither skin irritants nor sensitizers, and they do not cause eye irritation. 
Incompatibilities         :      It is incompatible with strong oxidizing agents. 
Uses                              :      As a tablet binder at a concentration of 5-85%, hydrophilic    
matrix former, mucoadhesive polymer as effective thickener. 
5.3. Ethylcellulose 
Ethylcellulose, an ethyl ether of cellulose, is a long-chain polymer of                              
β-anhydroglucose units joined together by acetal linkages. 
Synonyms                   :        Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
Description                 :        It is a tasteless, free-flowing, white to light tan-colored    
                                               powder. 
Functional Category   :       Coating agent; flavoring fixative; tablet binder; tablet filler;     
viscosity-increasing agent. 
Solubility              :      It is practically insoluble in glycerin, propylene glycol, and water. 
Ethylcellulose that contains less than 46.5% of ethoxyl groups is freely soluble in 
chloroform, methyl acetate, and tetrahydrofuran, and in mixtures of aromatic hydrocarbons 
with ethanol (95%).Ethylcellulose that contains not less than 46.5% of ethoxyl groups is 
freely soluble in chloroform, ethanol (95%), ethyl acetate, methanol, and toluene. 
Density (bulk)            :     0.4 g/cm
3
 
Viscosity                    :     7 to 100 mPa s 
Stability and Storage     :    It is a stable, slightly hygroscopic material. It should be stored 
at a temperature not exceeding 32°C (90°F) in a dry area away from all sources of heat. It 
should not be stored next to peroxides or other oxidizing agents. 
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Safety                   :   It is generally regarded as a nontoxic, nonallergenic, and nonirritating 
material. It is not metabolized following oral consumption and is therefore a noncalorific 
substance. 
Uses                                  :      It is used in the microencapsulation (10-20% w/w). 
                                        As a sustained-release tablet coating (3-20% w/w). 
                                        It can be used for tablet coating and tablet granulation  
                                        (1- 3% w/w). 
5.4. Kollidon
®
 SR 
Polyvinylacetate/Povidone based polymer (Kollidon® SR) is a relatively new 
extended release matrix excipient. It consists of 80% Polyvinylacetate and 19% Povidone 
in a physical mixture, stabilized with 0.8% sodium lauryl sulfate and 0.2% colloidal silica. 
(BASF, 1999; Ruchatz, 1999) 
Description                 :    It is a tasteless, free-flowing, non-hygroscopic, white powder. 
Functional Category  :   Direct compressible grade sustained release matrix former. 
Angle of Repose          :   21° 
Bulk Density               :   0.37 g/mL 
Tapped Density           :   0.44 g/mL 
Hausner’s Ratio          :   1.13 
Mean Particle Size       :   Approx. 100 m 
Uses                              :    It can be easily applied for controlled release properties by 
                                           direct compression. 
                                              It favours the development and manufacture of Sustained 
release tablets by its high dry binding capacity and the superb flow properties. 
Chapter-5                                                                            Polymer And Excipient Profile 
Dept  ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode  Page 44 
 
                                             It offers a reliable sustained release characteristic independent 
of the drug used. 
                                             By applying low compression force floating tablets with 
longer        residence time in the stomach can be achieved. 
                                             Floating times exceeding 24 hours can be achieved easily. 
5.5. Microcrystalline cellulose 
Microcrystalline cellulose is purified, partially depolymerized cellulose. 
Synonyms       :      Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG;  
                                    crystalline cellulose; E460; Emcocel; Ethispheres; Fibrocel;  
                                    Pharmacel; Tabulose; Vivapur. 
Description       :      It occurs as a white, odorless, tasteless, crystalline powder  
                                      composed of porous particles. 
Grades             : Avicel PH-101, PH-102, PH-103; Emcocel 50M,  90M; Vivapur 101, 102. 
Functional Category  :       Adsorbent; suspending agent; tablet and capsule diluent;      
                                           tablet disintegrant. 
Solubility            :       Slightly soluble in 5% w/v sodium hydroxide solution; practically  
                                 insoluble in water, dilute acids, and most organic solvents. 
Melting point                :     Chars at 260-270°C. 
Stability and Storage    :     It is a stable though hygroscopic material. The bulk material  
                                            should be stored in a well-closed container in a cool, dry place. 
Safety                            :      It is a relatively nontoxic and nonirritant material. 
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Uses                               :     It is widely used as a diluent (20 – 90 %w/w). 
                                             As a tablet disintegrant (5-15% w/w). 
                                             It can be used as an adsorbent, antiadherent (20-   90%w/w). 
5.6. Lactose monohydrate 
Lactose monohydrate as a natural disaccharide, obtained from milk, which consists 
of one galactose and one glucose moiety. 
Synonyms                      :     Lactochem, Pharmatose, NF Lactose, Capsulac, Granulac,   
                                             Tablettose, Inhalac,  Prismalac, Sachelac. 
Description                   :     White to off-white crystalline particles or powder, odorless     
                                          and slightly sweet-tasting; α-lactose is approximately 20% as  
                                          sweet as sucrose, while β-lactose is 40% as sweet.  
Functional Category   :    Binding agent; diluent for dry-powder inhalers; tablet    binder;  
                                          tablet and capsule diluent. 
Grades                          :      Lactochem powder, coarse powder, fine powder;                
                                              Pharmatose 50M, 80M, 90M, 100M, Inhalac 70, 120, 230; 
                                               Lactose monohydrate NF 80M. 
Solubility                      :      Soluble in water (1 in 5.24), practically insoluble in   
                                               chloroform, ethanol and ether. 
Angle of repose            :       33° for Pharmatose DCL 15;  
                                              32° for Tablettose 70 and Tablettose 80. 
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Melting point               :       201–202°C (for dehydrated α-lactose monohydrate) 
Density (true)      :       1.545 g/cm
3  
(α-lactose monohydrate) 
Safety                  :    Adverse reactions to lactose are largely attributed to lactose  
                               intolerance, which occurs in individuals with a deficiency of the  
                               intestinal enzyme lactase. This results in lactose being undigested and  
                                may lead to cramps, diarrhea, distension, and flatulence. 
Incompatibilities  :   A Maillard-type condensation reaction is likely to occur   between  
                                 lactose and compounds with a primary amine group to form brown, or  
                                 yellow-brown-colored products. Lactose is also incompatible with  
                                 amino acids, aminophylline, amfetamines, and lisinopril. 
Stability                 : Mold growth may occur under humid conditions (80% relative    
                                   humidity and above). Lactose may develop a brown coloration on  
                                    storage, the reaction being accelerated by warm, damp conditions. 
Storage                    : It should be stored in a well-closed container in a cool, dry  place. 
Uses                      : Widely used as a filler or diluent in tablets and capsules, and to a more  
                                limited extent in lyophilized products and infant formulas. It is also  
                                 used as a diluent in dry-powder inhalation. 
5.7. Povidone 
Synonyms                :  E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene];  
                                    polyvidone; polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone  
                                    polymer. 
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Grades                   :     PVP K-12, K-15, K-17, K-25, K-30, K-60, K-90, K-120. 
Functional Category  :       Disintegrant; dissolution aid; suspending agent; tablet binder. 
Description              :          It occurs as a fine, white to creamy-white colored, odorless or  
                                            almost odorless, hygroscopic powder. 
Melting point          :          Softens at 150°C. 
Solubility          :  Freely soluble in acids, chloroform, ethanol (95%), ketones,  
                              methanol, and water; practically insoluble in ether, hydrocarbons, and  
                              mineral oil. In water, the concentration of a solution is limited only by  
                              the viscosity of the resulting solution, which is a function of the K- 
                               value. 
Stability and Storage   :    Povidone darkens to some extent on heating at 150°C, with a  
                               reduction in aqueous solubility. It is stable to a short cycle of heat  
                               exposure around 110–130°C; steam sterilization of an aqueous solution  
                               does not alter its properties. Aqueous solutions are susceptible to mold  
                               growth and consequently require the addition of suitable preservatives.  
                                              It may be stored under ordinary conditions without  
                                 undergoing decomposition or degradation. However, since the powder  
                                is hygroscopic, it should be stored in an airtight container in a cool,  
                                dry place. 
 Incompatibilities      :       It is compatible in solution with a wide range of inorganic salts,  
                                 natural and synthetic resins, and other chemicals. It forms molecular  
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                                 adducts in solution with sulfathiazole, sodium salicylate, salicylic  
                                 acid, phenobarbital, tannin, and other compounds; the efficacy of  
                                 some preservatives, e.g. thimerosal, may be adversely affected by the  
                                 formation of complexes with povidone. 
Safety                        : When consumed orally, povidone may be regarded as  
                                  essentially nontoxic since it is not absorbed from the gastrointestinal  
                                   tract or mucous membranes. It additionally has no irritant effect on  
                                   the skin and causes no sensitization. 
Uses                     :  In tableting, povidone solutions (0.5-5% w/v) are used as binders in  
                                 wet-granulation processes. It is also added to powder blends in the dry  
                                 form and granulated in situ by the addition of water, alcohol, or  
                                 hydroalcoholic solutions. It is used as a solubilizer in oral and  
                                 parenteral formulations and has been shown to enhance dissolution  
                                 of poorly soluble drugs from solid-dosage forms. Povidone  
                                 solutions may also be used as coating agents. It is additionally used  
                                 as a suspending, stabilizing, or viscosity-increasing agent in number  
                                 of topical and oral suspensions and solutions. The solubility of a   
                                 number of poorly soluble active drugs may be increased by mixing  
                                 with povidone. 
 
 Chapter 6 
Methodology 
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6.METHODOLOGY 
          The materials used in the present investigation were either AR/LR grade or the 
best possible Pharma grade.  
MATERIALS USED 
 
S.NO 
 
MATERIAL 
 
SUPPLIED BY 
 
1 
 
Timolol maleate 
 
Neuland Laboratories,Hyderabad. 
 
2 
 
 HPMC K 15 M 
 
Neuland Laboratories,Hyderabad. 
 
3 
 
HPMC K 100 M 
 
Neuland Laboratories,Hyderabad. 
 
4 
  
Polyethylene Oxide 
 
Loba Chemie Pvt. Ltd, Mumbai. 
 
5 
 
Ethyl cellulose 
 
Loba Chemie Pvt. Ltd, Mumbai. 
 
6 
 
Kollidon-SR 
 
Neuland Laboratories,Hyderabad 
 
7 
 
Micro crystalline cellulose 
 
Loba Chemie Pvt. Ltd, Mumbai. 
 
8 
 
Polyvinyl pyrrolidone 
 
Loba Chemie Pvt. Ltd, Mumbai. 
 
9 
 
Isopropyl alcohol 
 
Loba Chemie Pvt. Ltd, Mumbai. 
 
10 
 
Magnesium state 
 
S.D Fine Chem Ltd.,Mumbai 
 
11 
 
Talc 
 
S.D Fine Chem Ltd.,Mumbai 
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EQUIPMENTS USED 
  Details of Equipments Used 
S. No. Instrument Manufacturer 
1. Electronic Weighing Balance Sartorious bt  2235, Japan. 
2. Tap Density Tester (U.S.P.) Electrolab, ETD-1020, India. 
3. Sieves Rolex standard sieves, India. 
4. Tablet punching machine Cadmach-cmd4 
5. Dissolution Apparatus (U.S.P.) Distek –2100c 
     6. Dissolution sampler HPLC Waters 2666 
7. Mill Quardo 
8. pH Meter L I 120, Elico Pvt. Ltd, India. 
9. Loss on drying tester Sartorious102 
10. Hardness Tester Varian-vk200 
11. UV Spectrophotometer Varian 21cfr-11  
12. Electromagnetic Sieve  Shaker EMS – 8 
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IDENTIFICATION TESTS:                                                                                                                                                                                                                                                 
       1) U V spectra :  
Dilute the 100 mg of drug sample in  phosphate buffer PH 6.8  and UV spectrum is 
obtained using a 1cm cell and scanning from 200 to 400nm. And compare the λ max value 
with the standard uv spectrum of Timolol maleate.                                                                                                                                                                                                                                                                                                                                                                              
       2) I R spectra:   
The FT-IR spectrum of pure Timolo maleate and physical mixture of Timolol 
maleate , HPMC K 100 M and Ethyl cellulose were analyzed for compatibility study. 
6.1. Construction of Standard Graph of Timolol Maleate 
 Accurately weigh the amount of 100 mg timolol maleate was transferred into a 
100ml volumetric flask. 20 ml of 0.1N hydrochloric acid (HCl) was added to dissolve the 
drug and volume was made up to 100 mL with the same HCl. The resulted solution had the 
concentration of 1mg/ml which was labeled as „stock‟. From this stock solution 10ml was 
taken and diluted to 100 mL with 0.1N HCl which has given the solution having the 
concentration of 100 mcg/mL. Necessary dilutions were made by using this second 
solution to give the different concentrations of timolol maleate (5 to 50 mcg/mL) solutions. 
The absorbances of above solutions were recorded at max (295 nm) of the drug 
using double beam UV-Visible spectrophotometer. Standard graph was plotted between 
the concentration (on X-axis) and absorbance (on Y-axis). 
Similarly, standard graph was plotted with 6.8 pH phosphate buffer. 
Preparation of 0.1 N HCl: Accurately measured 8.5 mL of concentrated hydrochloric 
acid was added to 1000 mL of distilled water. 
Preparation of pH 6.8 phosphate buffer:  Accurately measured 50 mL of 0.2 M 
potassium dihydrogen orthophosphate was transferred to a 200mL volumetric flask and 
22.4 mL of 0.2 M sodium hydroxide was added to it. Volume was made up to 200 mL with 
distilled water, mixed and pH was adjusted to 6.8 with 0.2 M sodium hydroxide or 0.2 M 
othophosphoric acid.  
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Preparation of 0.2 M potassium dihydrogen phosphate solution: Accurately weighed 
27.218 g of monobasic potassium dihydrogen phosphate was dissolved in 1000 mL of 
distilled water and mixed. 
Preparation of 0.2 M sodium hydroxide solution: Accurately weighed 8 g of sodium 
hydroxide pellets were dissolved in 1000 mL of distilled water and mixed. 
6.2. Calculation of Sustained-Release Dose and Theoretical Release     
Profile of Timolol Maleate 
             The total dose of timolol maleate for twice-daily SR formulation was calculated by 
Robinson Eriksen (Robinson and Eriksen, 1966) equation using available pharmacokinetic 
data. 
The zero-order drug release rate constant (k0) was calculated using following equation 
                                               k0 = DI x ke   
Where DI is the initial dose (i.e., conventional dose = 10 mg) and ke is first-order 
rate constant for overall elimination. 
ke   =   0.693 / t1/2     
Where t1/2 = Biological half-life of timolol maleate = 4 h     
                         Therefore         ke = 0.693 / 4                
                                                       = 0.1732 mg/h. 
                       Availability rate  R =  ke x DI 
                                                       = 0.1732 x 10 
                                                       = 1.732 mg/h. 
                       Loading dose = DL = DI – R x tmax 
                             where tmax  = 2 h 
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                         Therefore DL = 10-(1.732 x 2) 
                                                = 6.54 mg. 
 Maintenance dose = DM = R x H 
 where H = Number of hours for which sustained action is desired after initial release.   
Therefore DM = 1.732 x 11 
= 19.05 mg. 
                       Total dose required = DT = DL + DM 
                                         = 6.54+19.05 
                                         = 25.59 mg 
                                         25 mg       
            Hence an oral controlled release formulation of timolol maleate should contain a 
total dose of   25 mg and should release 6.54 mg in first 1 hour like conventional tablets, 
and 1.73 mg/h up to 12 hours thereafter.             
6.3. Preparation of Timolol Maleate Matrix Tablets 
            All the matrix tablets, each containing 25 mg of timolol maleate, were prepared by 
wet granulation method and some of the formulations were prepared by direct compression 
method also to study the effect of method of manufacture on the drug release. 
Wet granulation: Drug and the diluent (MCC or Lactose) were sifted through sieve No. 
40 manually and mixed well to ensure the uniformity of premix blend. Several drug-
diluent premixes were then mixed with the selected ratio of polymer(s), previously sifted 
through sieve No. 40, for 5 minutes. Premix blend was wet granulated with 5% w/v 
solution of PVP K-90 in a mortar. The wet mass was passed through No.18 sieve. The wet 
granules were dried at 55°C ± 5°C for 1 hour in a hot-air oven and the dried granules were 
sieved through No.22 sieve. 
Chapter-6                                                                                                           Methodology 
Dept  ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode  Page 54 
 
                These granules were blended with lubrication mixture (1% w/w magnesium 
stearate and 2% w/w talc) and compressed using 16 station rotary   tableting machine, 
equipped with flat-faced, round punches of 6-mm diameter. 
Direct compression: Accurately weighed amounts of drug, polymer, and diluent were 
mixed geometrically in a mortar. This mixture was passed through No.40 sieve and 
thoroughly mixed in a polythene bag for 15 minutes. The powder blend was then 
lubricated with magnesium stearate and talc for 2 minutes and compressed into tablets on a 
16-station rotary tableting machine using 6-mm round, flat-faced punches. 
           The drug polymer ratio was developed to adjust drug release as per theoretical 
release profile and to keep total weight of tablet constant for all the fabricated batches 
under experimental conditions of preparations. The total weight of the matrix tablets was 
120mg with different drug polymer ratios like 1:0.5, 1:1, 1:1.5, 1:2. The various polymers 
used were HPMC K15M, Polyethylene oxide, Kollidon-SR, HPMC K100M CR and Ethyl 
cellulose. Diluents like MCC (water-insoluble) or lactose (water soluble) were used for the 
preparation of matrix tablets. 
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Table 5. List of Different Formulations 
 
Formulae Polymer (s)  Diluent         Method 
F1 to F4 HPMC K15M MCC Wet granulation 
F5 to F8 Polyethylene oxide MCC Wet granulation 
F9 to F12 HPMC K 100M MCC Wet granulation 
F13 to F16 Ethyl cellulose MCC Wet granulation 
F17 to F20 Kollidon-SR MCC Direct compression 
F21 to F25 HPMC K100M & EC MCC Wet granulation 
F26 to F30 HPMC K 100M 
&HPMC K 15M 
MCC Wet granulation 
 
 
 
 
 
 
 
 
Chapter-6                                                                                                           Methodology 
Dept  ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode  Page 56 
 
 6.4. Formulations 
         In the formulations prepared, the release retardants included were 
hydroxypropylmethylcellulose (HPMC K15M, HPMC K100M CR), polyethylene oxide 
(PEO), ethylcellulose (EC), and Kollidon-SR. Microcrystalline cellulose (MCC), lactose 
were used as diluents. Magnesium stearate (MS) 1% and talc 2 % were used as lubricants. 
5% w/v solution of polyvinylpyrrolidone (PVP-K90) in isopropyl alcohol (IPA) was used 
as binder. Compositions of different formulations were given in the following Tables 
(Table 6 to Table 12). 
Table 6. Composition of Matrix Tablets Containing HPMC K15M
* 
F.Code  TM 
(mg) 
HPMC     
K15M 
  (mg) 
 MCC  
 (mg) 
 PVP-          
K90 
(mg) 
IPA 
(mL) 
  MS 
 (mg) 
Talc 
(mg) 
Total 
(mg) 
F1 25 12.5 72.9 6 qs 1.2 2.4 120 
F2 25 25 60.4 6 qs 1.2 2.4 120 
F3 25 37.5 47.9 6 qs 1.2 2.4 120 
F4 25 50 35.4 6 qs 1.2 2.4 120 
      * qs = quantity sufficient; Drug to Polymer ratio is 1:0.5, 1:1, 1:1.5, and 1:2 for  
       F1, F2, F3, and F4 respectively. 
 
Table 7. Composition of Matrix Tablets Containing Polyethylene Oxide 
F.Code TM 
(mg) 
PEO 
(mg) 
MCC 
(mg) 
PVP-          
K90 
(mg) 
IPA 
(ml) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F5 25 12.5 72.9 6 qs 1.2 2.4 120 
F6 25 25 60.4 6 qs 1.2 2.4 120 
F7 25 37.5 47.9 6 qs 1.2 2.4 120 
F8 25 50 35.4 6 qs 1.2 2.4 120 
      * qs = quantity sufficient; Drug to Polymer ratio is 1:0.5, 1:1, 1:1.5, and 1:2 for  
       F5, F6, F7, and F8 respectively. 
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Table 8. Composition of Matrix Tablets Containing HPMC K100M CR
* 
F.Code TM 
(mg) 
HPMC K 
100M 
(mg) 
MCC 
(mg) 
PVP-          
K90 
(mg) 
IPA 
(ml) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F9 25 12.5 72.9 6 qs 1.2 2.4 120 
F10 25 25 60.4 6 qs 1.2 2.4 120 
F11 25 37.5 47.9 6 qs 1.2 2.4 120 
F12 25 50 35.4 6 qs 1.2 2.4 120 
      * qs = quantity sufficient; Drug to Polymer ratio is 1:0.5, 1:1, 1:1.5, and 1:2 for  
       F9, F10, F11, and F12 respectively. 
 
Table 9. Composition of Matrix Tablets Containing Ethylcellulose
* 
F.Code TM 
(mg) 
EC  
(mg) 
MCC 
(mg) 
PVP-          
K90 
(mg) 
IPA 
(mL) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F13 25 12.5 72.9 6 qs 1.2 2.4 120 
F14 25 25 60.4 6 qs 1.2 2.4 120 
F15 25 37.5 47.9 6 qs 1.2 2.4 120 
F16 25 50 35.4 6 qs 1.2 2.4 120 
     * qs = quantity sufficient; Drug to Polymer ratio is 1:0.5, 1:1, 1:1.5, and 1:2 for F13,  
     F14, F15, and F16 respectively. 
 
Table 10. Composition of Matrix Tablets Containing Kolliodon-SR
*
 
F.code TM 
(mg) 
Kollidon-
SR (mg) 
MCC 
(mg) 
PVP-          
K90 
(mg) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F17 25 12.5 72.9 6 1.2 2.4 120 
F18 25 25 60.4 6 1.2 2.4 120 
F19 25 37.5 47.9 6 1.2 2.4 120 
F20 25 50 35.4 6 1.2 2.4 120 
           
*
 Drug to Polymer ratio is 1:0.5, 1:1, 1:1.5, and 1:2 for F17, F18, F19, and  
            F20  respectively. 
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Table 11. Composition of Matrix Tablets Containing Combination of 
HPMC K100M and EC
*
 
F.Code TM 
(mg) 
HPMC     
K100M 
(mg) 
EC 
(mg) 
MCC 
(mg) 
PVP-          
K90 
(mg) 
IPA 
(mL) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F21 25 40 10 35.4 6 qs 1.2 2.4 120 
F22 25 30 20 35.4 6 qs 1.2 2.4 120 
F23 25 25 25 35.4 6 qs 1.2 2.4 120 
F24 25 20 30 35.4 6 qs 1.2 2.4 120 
F25 25 10 40 35.4 6 qs 1.2 2.4 120 
      
*
 qs = quantity sufficient; Drug to Polymer ratio is 1:2; HPMC to EC ratio is 4:1, 3:2, 
1:1, 2:3, and 1:4 for F21, F22, F23, F24, and F25 respectively. 
  
Table 12. Composition of Matrix Tablets Containing Combination of 
HPMC K100M and HPMC K15M
*
 
F.Code TM 
(mg) 
HPMC 
K100M      
(mg) 
HPMC 
K15M 
(mg) 
MCC 
(mg) 
PVP-          
K90 
(mg) 
IPA 
(mL) 
MS 
(mg) 
Talc 
(mg) 
Total 
(mg) 
F26 25 40 10 35.4 6 qs 1.2 2.4 120 
F27 25 30 20 35.4 6 qs 1.2 2.4 120 
F28 25 25 25 35.4 6 qs 1.2 2.4 120 
F29 25 20 30 35.4 6 qs 1.2 2.4 120 
F30 25 10 40 35.4 6 qs 1.2 2.4 120 
       
*
qs = quantity sufficient; Drug to Polymer ratio is 1:2; HPMC K100M to HPMC 
K15M  ratio is 4:1, 3:2,1:1, 2:3, and 1:4 for F26, F27, F28, F29, and  F30 respectively. 
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6.5.  Evaluation of Precompression Blend 
  a)   Angle of Repose 
           The angle of repose is the maximum angle that the plane of powder makes with the 
horizontal surface on rotation . Angle of repose is helpful in assessment of flow properties 
of particles which could be further related to packing densities and mechanical 
arrangements of particles.      
             The angle of repose of granules was determined by the funnel-method. The 
accurately weighed granules were taken in a funnel. The height of the funnel was adjusted 
in such a manner that the tip of the funnel just touched the apex of the heap of the 
granules. The granules were allowed to flow through the funnel freely onto the surface. 
The diameter of the powder cone measured and angle of repose was calculated using the 
following equation (Raghuram et al., 2003). 
                                                  tan θ  = h/r 
  where h =  height of the powder heap 
            r   =   radius of the powder heap 
            θ   =   angle of repose 
    Table 13: Significance of Angle Of  Repose       
   
S.No. Angle of repose Flow property 
1 <25 Excellent 
2 25-30 Good 
3 30-40 Passable 
4 >40 Poor 
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b) Determination of Bulk Density and Tapped Density 
             An accurately weighed quantity of the granules/ powder (W) was carefully poured 
into the graduated cylinder and volume (V0) was measured. Then the graduated cylinder 
was closed with lid and set into the tap density tester (USP). The density apparatus was set 
for 100 tabs and after that the volume (Vf) was measured and continued operation till the 
two consecutive readings were equal (Lachman et al., 1987). 
            The bulk density and the tapped density were calculated using the following 
formulae. 
                                   Bulk density = W/V0 
                                  Tapped density = W/Vf 
                         where, W= Weight of the powder 
                                     V0 = Initial volume 
                                      Vf = final volume 
c) Compressibility Index (Carr’s Index) 
           Carr‟s index (CI) is an important measure that can be obtained from the bulk and 
tapped densities. In theory, the less compressible a material the more flowable it is 
(Lachman et al., 1987). 
                                    CI = (TD-BD) x 100/TD    
      where, TD is the tapped density and BD is the bulk density. 
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Table 14.Carr’s Index Values 
 S.No. Carr’s Index Properties 
1 5-12 Free flowing 
2 13-16 Good 
3 18-21 Fair 
4 23-35 Poor 
5 33-38 Very poor 
6 >40 Extremely poor 
              
d)  Hausner’s Ratio        
 It is the ratio of tapped density and bulk density. Hausner found that this ratio was 
related to interparticle friction and, as such, could be used to predict powder flow 
properties (Lachman et al., 1987). Generally a value less than 1.25 indicates good flow 
properties, which is equivalent to 20% of Carr‟s index 
Hausener’s Ratio    =   Tapped density/Bulk Density 
Table 15: Significance of Hausener’s Ratio: 
S.No Hausner’s Ratio Property 
1 01.2 Free flowing 
2 1.21.6 Cohesive powder 
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6.6. Evaluation of Matrix Tablets 
i) Thickness 
               Twenty tablets from the representative sample were randomly taken and 
individual tablet thickness was measured by using digital vernier caliper. Average 
thickness and standard deviation values were calculated. 
ii) Hardness 
 Tablet hardness was measured by using Monsanto hardness tester. From each batch 
six tablets were measured for the hardness and average of six values was noted along with 
standard deviations. 
iii) Friability Test 
          From each batch, ten tablets were accurately weighed and placed in the friability test 
apparatus (Roche friabilator). Apparatus was operated at 25 rpm for 4 minutes and tablets 
were observed while rotating. The tablets were then taken after 100 rotations, dedusted and 
reweighed. The friability was calculated as the percentage weight loss. 
Note: No tablet should stick to the walls of the apparatus. If so, brush the walls with 
talcum powder. There should be no capping also. 
% friability was calculated as follows             
                                 % Friability = (W1 – W2) x 100/W1 
                             where W1 = Initial weight of the 20 tablets. 
                                       W2 = Final weight of the 20 tablets after testing. 
Friability values below 0.8% are generally acceptable. 
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iv) Weight Variation Test  
           To study weight variation individual weights (WI) of 20 tablets from each 
formulation were noted using electronic balance. Their average weight (WA) was 
calculated. Percent weight variation was calculated as follows. Average weights of the 
tablets along with standard deviation values were calculated. 
                            % weight variation = (WA–WI) x 100/ WA 
 As the total tablet weight was 120 mg, according to IP 1996, out of twenty tablets 
±7.5 % variation can be allowed for not more than two tablets. 
           According to USP 2004, ±10% weight variation can be allowed for not more than 
two tablets out of twenty tablets. 
v) Drug Content (Assay) 
           The drug content of the matrix tablets was determined according to in-house 
standards and it meets the requirements if the amount of the active ingredient in each of 
the 10 tested tablets lies within the range of 90% to 110% of the standard amount. 
            Ten tablets were weighed and taken into a mortar and crushed into fine powder. An 
accurately weighed portion of the powder equivalent to about 100 mg of TM was 
transferred to a 100 mL volumetric flask containing 70 mL of 0.1N HCl. It was shaken by 
mechanical means for 1h.Then it was filtered through a Whatman filter paper (No. 1) and 
diluted to 100 mL with 0.1N HCl. From this resulted solution 1 mL was taken, diluted to 
50 mL with 0.1N HCl and absorbance was measured against blank at 295 nm.                 
vi) In -Vitro Drug Release Characteristics 
Drug release was assessed by dissolution test under the following conditions: n = 3,  
USP type II dissolution apparatus  (paddle method) at 100 rpm in 500 mL of  0.1N HCl for 
first 2 hours and the phosphate buffer pH 6.8 from 3 to 12 hours, maintained at 37°C ± 
0.5°C.  An aliquot (5mL) was withdrawn at specific time intervals and replaced with the 
same volume of prewarmed (37°C ± 0.5°C) fresh dissolution medium. The samples 
withdrawn were filtered through Whatman filter paper (No.1) and drug content in each 
sample was analyzed by UV-visible spectrophotometer at 295 nm.     
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Details of dissolution test:  
Dissolution test apparatus  : USP II  
Speed     : 100±0.1 rpm 
Stirrer    : paddle type 
Volume of medium   : 500 ml 
Time interval                                    : 1, 2, 3,4,6,8,10 and 12 hours  
Medium used    : 0.1N HCl for first 2 hours and the phosphate       
                                                                buffer pH 6.8 from 3 to 12 hours   
Temperature    : 37 ± 0.5 
0
C 
vii) Kinetic Analysis of Dissolution Data 
             To analyze the in vitro release data various kinetic models were used to describe 
the release kinetics. The zero order rate Eq. (1) describes the systems where the drug 
release rate is independent of its concentration (Hadjiioannou et al., 1993). The first order 
Eq. (2) describes the release from system where release rate is concentration dependent 
(Bourne, 2002). Higuchi (1963) described the release of drugs from insoluble matrix as a 
square root of time dependent process based on Fickian diffusion Eq. (3). The Hixson-
Crowell cube root law Eq. (4) describes the release from systems where there is a change 
in surface area and diameter of particles or tablets (Hixson and Crowell, 1931). 
                  C = K0 t                                                                                                   (1)                  
Where, K0 is zero-order rate constant expressed in units of concentration/time and t 
is the time. 
      LogC = LogC0  - K1 t / 2.303                                                                   (2) 
Where, C0 is the initial concentration of drug and K1 is first order constant. 
                 Q = KHt
1/2                    
                                                                                     (3) 
Where, KH is the constant reflecting the design variables of the system. 
           
                  Q0
1/3
 – Qt
1/3
 = KHC t                                                                                   (4) 
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where, Qt is the amount of drug remained in time t, Q0 is the initial amount of the drug in 
tablet and KHC is the rate constant for Hixson-Crowell rate equation. 
The following plots were made using the in-vitro drug release data 
Cumulative % drug release vs. time (Zero order kinetic model); 
Log cumulative of % drug remaining vs. time (First order kinetic model); 
Cumulative % drug release vs. square root of time (Higuchi model); 
And cube root of initial concentration minus the cube root of percentage of drug remaining 
in the matrix vs. time (Hixson-Crowell cube root law). 
viii) Mechanism of drug release 
             Korsmeyer et al (1983) derived a simple relationship which described drug release 
from a polymeric system Eq. (5). To find out the mechanism of drug release, first 60% 
drug release data was fitted in Korsmeyer–Peppas model. 
Mt / M∞ = Kt
n
                                                                    (5)              
Where Mt / M∞ is fraction of drug released at time t, K is the release  rate constant 
incorporating structural and geometric characteristics of the tablet, and n is the release 
exponent. The n value is used to characterize different release mechanisms.  
           A plot of log cumulative % drug release vs. log time was made. Slope of the line 
was n. The n value is used to characterize different release mechanisms as given in 
Table16, for the cylindrical shaped matrices. Case-II generally refers to the erosion of the 
polymeric chain and anomalous transport (Non-Fickian) refers to a combination of both 
diffusion and erosion controlled-drug release (Peppas, 1985). 
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Table  16 .   Diffusion Exponent and Solute Release Mechanism for Cylindrical Shape 
 
 
 
 
 
 
 
 
 
 
 
ix) Similarity Factor (f2) Analysis 
In vitro release profiles of the selected batches (F12 and F23) of sustained release 
tablets were compared with the theoretical release profile which was calculated earlier. 
The data were analyzed by the following formula ((Bolton and Bon., 2004). 
                                f2 = 50 log {[1+ (1/N) ∑ (Ri – Ti)
2 
]
-0.5
 x 100}                                          
Where N = number of time points, Ri and Ti = dissolution of reference and test 
products at time i. If f2 is greater than 50 it is considered that 2 products share similar drug 
release behaviors. 
x) Swelling and Erosion Studies 
             Swelling and eroding behavior was determined by a method similar to that 
reported by Avachat and Vikram (Avachat and Vikram, 2007).The dissolution jars were 
marked with the time points of   0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours. One tablet was 
placed in each dissolution jar containing 500 mL of 0.1 N HCl at 37 °C ± 0.5 °C, and the 
apparatus was run at 100 rpm using paddle. After 2 hours, 0.1 N HCl was replaced with 
500 mL of phosphate buffer pH 6.8. The tablets were taken out after completion of the 
respected stipulated time span as mentioned above and weighed after the excess of water at 
the surface had been removed with filter paper. The wetted samples were then dried in an 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45 < n < 0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n > 0.89 Super case-II transport 
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oven at 40 °C up to constant weight. The increase of the weight on the tablet reflects the 
weight of the liquid uptake. It was estimated according to following equation  
                                           Q = 100(Ww – Wi) / Wi              
Where Q is the percentage swelling, and Ww and Wi are the masses of the 
hydrated samples before drying and the initial starting dry weight, respectively (Lopes et 
al., 2006). 
The degree of erosion (expressed as percentage erosion of the polymer content, E) 
was determined using following equation. 
                                         E = 100(Wi – Wf) / Wi                                                                                      
where Wf is the final mass of the same dried and partially eroded sample.  
xi) FTIR Studies 
           FTIR studies were performed on drug and the optimized formulation using 
Shimadzu FTIR (Shimadzu Corp., India). The samples were analyzed between wave 
numbers 4000 and 400 cm
-1
. 
Xii) Stability studies of the optimized formulation:  
Stability of a pharmaceutical preparation can be defined as “the capability of a 
particular formulation in a specific container/closure system to remain within its physical, 
chemical, microbiological, therapeutic and toxicological specifications throughout its shelf 
life.” 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under influence of a variety of environmental 
factors such as temperature, humidity and light, and enables recommended storage 
conditions, re-test periods and shelf-lives to be established. 
ICH specifications for stability study: 
 Long term testing: 250C ± 20C /60% RH ± 5% RH for 12 months. 
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 Accelerated testing: 400C ± 20C /75% RH ± 5% RH for 6 months. 
Procedure: 
 In the present study, stability studies were carried out at 40 
0
C and 75% RH for a 
specific time period up to 60 days for optimized formulations. 
 For stability study, the tablets were sealed in aluminum packaging coated inside 
with polyethylene. These sample containers were placed in desiccator‟s maintained at 75% 
RH. 
NOTE: Saturated solution of sodium chloride at 40
0
C yields a 75% relative humidity. 
Evaluation of samples: 
 The samples were analyzed for the following parameters: 
I.Physical evaluation: 
Appearance: The samples were checked for any change in colour at every month. 
II.Chemical evaluation: 
Drug content: The samples were checked for drug content. 
Drug release: The samples were subjected to drug release studies. 
 Chapter 7 
Results 
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RESULTS 
 7.1. Standard Graph of Timolol Maleate 
            The standard graph of Timolol maleate ((Table. 17) has shown good linearity with 
R
2
 values 0.9956 and 0.9968 in 0.1 N HCl (Fig. 3) and pH 6.8 buffer (Fig. 4) respectively 
under λmax of 295nm, which suggests that it obeys the “Beer-Lambert’s  law”. 
                           Table 17.  Standard Graph of Timolol Maleate 
Conc. 
(mcg/mL) 
Absorbance at 295nm 
0.1N HCl 6.8 pH Buffer 
5 0.159 0.135 
10 0.208 0.248 
15 0.318 0.352   
20 0.428 0.433 
25 0.512 0.535 
30 0.605 0.671 
35 0.718 0.759 
40 0.860 0.858 
45 0.932 0.934 
50 1.009 1.011 
R
2 
0.9956 0.9968 
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Figure 3. Standard graph of timolol maleate in 0.1 N HCl 
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Figure  4. Standard graph of timolol maleate in 6.8 pH buffer 
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7.2. Dose Calculations and Theoretical Release Profile 
           As calculated before, the total dose required for twice-daily SR formulation of 
timolol maleate was found to be 25 mg and its theoretical release profile was given in 
Table 18.         
Table 18. Theoretical Release Profile of Timolol Maleate from SR tablets 
Time (hours) Cumulative % Release 
1 26.16 
2 33.08 
3 40 
4 46.92 
6 60.76 
8 74.6 
10 88.44 
12 > 90 
 
 
7.2. Characterization of Granules 
               The granules for matrix tablets were characterized with respect to angle of 
repose, bulk density, tapped density, Carr’s index, and drug content (Table 19). Angle of 
repose was less than 35° and Carr’s index values were less than 21 for the granules of all 
the batches indicating good to fair flowability and compressibility. Hausner’s ratio was 
less than 1.25 for all the batches indicating good flow properties. The drug content was 
more than 90 % for all the granules of different formulations. 
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Table 19. Physical Properties of Precompression Blend : 
Formulations Angle of 
repose ( ° ) 
Bulk 
Density 
(g/mL) 
Tapped 
Density 
(g/mL) 
Carr’s 
Index (%) 
Hausner’s 
ratio 
F1 25.49 0.214 0.251 14.74 1.17 
F2 26.24 0.308 0.364 15.38 1.18 
F3 29.05 0.276 0.322 14.28 1.16 
F4 26.97 0.341 0.388 12.11 1.13 
F5 29.25 0.324 0.376 13.82 1.16 
F6 32.27 0.320 0.397 19.39 1.24 
F7 33.65 0.521 0.629 17.17 1.20 
F8 33.21 0.518 0.627 17.38 1.21 
F9 26.56 0.422 0.506 16.60 1.19 
F10 28.75 0.481 0.572 
15.90 1.18 
F11 27.33 0.475 0.566 16.07 1.19 
F12 25.38 0.524 0.599 12.52 1.14 
F13 26.43 0.412 0.483 14.69 1.17 
F14 24.77 0.488 0.537 9.12 1.10 
F15 26.42 0.439 0.521 15.73 1.18 
F16 28.19 0.559 0.649 
13.94 1.16 
F17 29.58 0.331 0.393 15.77 1.18 
F18 28.73 0.362 0.428 15.42 1.18 
F19 30.45 0.386 0.473 18.39 1.22 
F20 26.43 0.375 0.442 15.15 1.17 
F21 19.29 0.434 0.497 12.67 1.14 
F22 21.25 0.520 0.582 
10.65 1.11 
F23 26.27 0.487 0.561 13.19 1.15 
F24 25.49 0.494 0.566 12.72 1.14 
F25 27.88 0.544 0.643 15.39 1.18 
F26 27.34 0.510 0.591 13.70 1.15 
F27 28.77 0.533 0.617 13.61 1.15 
F28 28.47 0.498 0.582 
14.43 1.16 
F29 32.51 0.539 0.652 17.33 1.20 
F30 33.17 0.482 0.589 18.16 1.22 
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7.3Evaluation of matrix tablets: 
The results of the uniformity of weight, hardness, thickness, friability, and drug 
content of the tablets are given in Table 20. All the tablets of different batches complied 
with the official requirements of uniformity of weight as their weights varied between 
118.4 and 122.3 mg. The hardness of the tablets ranged from 5.08 to 6.16 kg/cm
2
 and the 
friability values were less than 0.8% indicating that the matrix tablets were compact and 
hard. The thickness of the tablets ranged from 2.88 to 3.40 mm. All the formulations 
satisfied the content of the drug as they contained 90 to 103 % of timolol maleate and good 
uniformity in drug content was observed. Thus all the physical attributes of the prepared 
tablets were found be practically within control. 
 
Table 20. Physical Evaluation of Matrix Tablets 
 
F.Code Hardness 
(kg/cm
2
) † 
Thickness 
(mm) ‡ 
Weight 
(mg) ‡ 
Friability 
(%) 
Drug content 
* (%) 
F1 5.50 ±0.44 3.22±0.17 119.8±1.48 0.36 98.25±1.37 
F2 5.50±0.31 3.37±0.25 120.4±0.54 0.39 95.28±0.80 
F3 5.58±0.40 3.14±0.80 118.6±0.41 0.43 99.12±2.47 
F4 5.66±0.55 3.20±0.20 118.8±1.64 0.12 101.22±0.88 
F5 4.25±0.57 3.08±0.66 120.6±1.14 0.54 100.24±1.25 
F6 4.08±0.30 3.33±0.25 119.2±0.83 0.58 99.53±1.87 
F7 4.25±0.57 3.24±0.71 119.9±0.67 0.64 93.28±1.99 
F8 4.41±0.60 3.32±0.89 119.0±0.43 0.37 95.35±1.14 
F9 5.00±0.44 3.38±0.73 120.5±0.80 0.77 96.34±2.18 
F10 5.00±0.31 3.00±0.68 121.2±0.83 0.42 91.29±0.98 
F11 5.08±0.37 2.98±0.88 122.1±0.93 0.48 97.35±0.43 
F12 5.41±0.70 3.11±0.36 121.2±0.97 0.15 98.88±0.88 
F13 4.33±0.50 3.06±0.46 119.2±0.83 0.27 94.57±1.22 
F14 4.58±0.57 2.98±0.38 122.2±0.92 0.29 90.35±2.09 
F15 4.75±0.77 3.25±0.37 122.0±1.22 0.53 99.54±2.15 
Chapter-7                                                                                                                                    Results  
 
Dept ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode  Page 74 
 
 
 
* All values represent mean ± Standard Deviation (SD), n=3 
 
† All values represent mean ± Standard Deviation (SD), n=6 
 
‡ All values represent mean ± Standard Deviation (SD), n=20 
 
 
 
 
 
 
 
 
F.Code Hardness 
(kg/cm
2) † 
Thickness 
(mm) ‡ 
 
 
Weight 
(mg) ‡ 
Friability 
(%) 
Drug content * 
(%) 
F16 4.91±0.80 3.24±0.52 120.8±1.48 0.64 102.55±2.31 
F17 5.08±0.86 3.15±0.56 118.4±1.04 0.71 93.78±1.56 
F18 5.16±0.75 3.20±0.44 121.4±1.09 0.42 96.27±1.88 
F19 5.25±0.67 3.11±0.55 120.7±0.65 0.66 92.55±1.56 
F20 5.30±0.47 3.31±0.56 120.1±1.82 0.38 102.87±0.97 
F21 5.41±0.69 2.95±0.75 122.3±0.84 0.86 100.68±1.39 
F22 5.58±0.37 2.93±0.83 119.8±0.19 0.69 95.39±2.06 
F23 5.66±0.65 3.33±0.59 119.8±0.38 0.37 98.90±2.31 
F24 5.75±0.57 3.36±0.74 121.3±0.97 0.51 97.43±2.11 
F25 6.16±0.70 3.32±0.65 122.9±0.90 0.59 97.66±2.04 
F26 4.66±0.35 3.15±0.71 121.5±0.96 0.28 102.82±1.55 
F27 5.08±0.37 3.26±0.43 120.2±0.76 0.35 100.44±1.21 
F28 5.16±0.65 3.35±0.50 120.6±1.48 0.47 99.21±2.07 
F29 
5.25±0.57 3.31±0.44 120.9±0.99 0.21 91.99±2.81 
F30 
5.25±0.97 3.30±0.27 120.5±1.01 
0.33 
90.76±2.54 
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7.4. In-Vitro Drug Release Studies 
Drug Release from HPMC K15M Matrices  
           The results of release studies of formulations F1 to F4 are shown in Table 21 and 
Figure 5. The release of drug depends not only on the nature of matrix but also upon the 
drug polymer ratio. As the percentage of polymer increased, the kinetics of release 
decreased. Formulation F1 composed of drug polymer ratio of 1:0.5, failed to sustain 
release beyond 6h. This formulation underwent erosion before complete swelling could 
take place. Formulations with drug polymer ratios 1:1 (F2), 1:1.5 (F3) have extended the 
drug release for 8h. Further increasing the ratio to 1:2 (F4), the release was sustained for 
10 h. All these formulations have shown more than 30% release in the first 1 hour 
indicating burst release. This phenomenon may be attributed to surface erosion or initial 
disaggregation of the matrix tablet prior to gel layer formation around the tablet core 
(Ebube et al., 1997). It is reported in the literature that more than 30% release of drug in 
the first hour of dissolution indicates the chance of dose dumping (Atul et al., 2006). 
Table 21. In-Vitro Release Data of Timolol Maleate from HPMC K15M Matrices
* 
  
 
 
*
All values represent mean cumulative percent drug released ± SD (n=3) 
Time (hours) F1 F2 F3 F4 
1 41.94±0.87 39.96±0.93 37.12±1.22 36.78±1.53 
2 53.88±0.44 50.99±0.68 50.20±0.37 48.13±1.12 
3 74.58±1.10 67.43±0.49 63.09±0.96 62.99±0.84 
4 82.35±1.35 80.50±1.77 77.61±0.42 75.35±0.59 
6 94.28±1.79 89.47±1.35 86.23±1.49 83.30±0.97 
8 - 97.55±0.21 93.83±0.74 91.15±0.68 
10 - - - 98.47±0.81 
12 - - - - 
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Figure 5. Release Profiles of Timolol Maleate from HPMC K15M Matrices 
  
 
 
Drug Release from Polyethylene Oxide Matrices  
               High molecular weight polyethylene oxides have recently been proposed as an 
alternative to HPMC in controlled release matrix tablets. As shown in Table 22 and Figure 
6, the drug release was extended up to 6h with initial burst release for the formulation F5. 
Further increase in the concentration of polymer the drug release was decreased slightly 
(97.19%, 92.57% and 90.77% at 8 hours for F6, F7 and F8, respectively). No burst release 
was observed during first hour for the formulations F6, F7, and F8 with release of 28.81%, 
25.56%, and 22.38% respectively. PEO matrices have shown faster drug release compared 
to HPMC containing formulations. Similar findings were reported by Maggi et al., 2000. 
They reported that slower release rates can be obtained from the matrices containing 
HPMC compared to PEO. 
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Table 22. In-Vitro Drug Release Data of Timolol Maleate from Polyethylene Oxide 
                 Matrices
*
 
 
Time (hours) F5 F6 F7 F8 
1 32.90±1.25 28.81±0.79 25.56±0.47 22.38±0.96 
2 44.14±0.58 40.35±0.43 37.36±1.68 35.23±0.88 
3 58.23±0.97 55.46±0.74 54.48±1.53 51.66±0.91 
4 73.74±1.19 69.38±0.95 66.55±1.49 63.48±0.65 
6 92.30±0.58 84.68±0.52 82.43±1.27 79.57±0.85 
8 - 97.19±1.43 92.57±1.36 90.77±0.64 
10 - - - - 
12 - - - - 
 
*
All values represent mean cumulative percent drug released ± SD (n=3) 
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Figure 6. Release Profiles of Timolol Maleate from Polyethylene Oxide Matrices 
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Drug Release from HPMC K100M CR Matrices  
            Low molecular weight HPMC is used predominantly for tablet film coating, while 
high molecular weight HPMC is used as rate-controlling polymer to retard the release of 
drugs from a matrix at levels of 10% to 80% w/w in tablets and capsules (Raymond and 
Paul, 2003). Results for the drug release from HPMC K100M matrices showed in Table 23 
and Figure 7. Formulations containing HPMC K100M (F9 to F12) have shown initial burst 
release and extended the release for 8 to 12h. As the drug polymer ratio increased to 1:2 
(F12), the kinetics of release decreased (98.97% at 12h). The drug release was slower from 
matrices containing HPMC K100M compared to HPMC K15M. This may be due to 
structural reorganization of HPMC. Increase in concentration and viscosity of HPMC may 
result in increase in the tortuosity or gel strength of the polymer. When HPMC is exposed 
to aqueous medium, it undergoes rapid hydration and chain relaxation to form viscous 
gelatinous layer (gel layer). Failure to generate a uniform and coherent gel may cause rapid 
drug release (Basak et al., 2006). 
           Similar findings were reported by Amelia and Vikram, 2007 and Basak et al, 2006. 
They revealed that 30-40% HPMC K100M was able to extend the release of water 
soluble drugs for more than 8 h. 
 
Table 23. In -Vitro Release Data of Timolol Maleate from HPMC K100M Matrices
*
 
 
Time (hours) F9 F10 F11 F12 
1 37.23±0.97 35.38±1.47 35.16±1.32 34.93±0.58 
2 51.72±1.68 50.46±0.83 50.08±1.27 49.86±0.94 
3 71.58±0.87 69.17±0.65 67.58±0.94 66.97±0.75 
4 80.71±0.54 78.32±0.87 77.73±1.57 76.82±0.38 
6 89.43±1.63 86.87±0.42 83.83±0.59 81.87±0.96 
8 97.29±0.53 94.55±0.74 90.87±1.79 89.89±0.72 
10 - 98.25±1.62 96.14±1.05 93.07±0.82 
12 - - - 98.97±0.27 
*
All values represent mean cumulative percent drug released ± SD (n=3) 
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Figure 7. Release Profiles of Timolol Maleate from HPMC K100M Matrices 
 
Drug Release from Ethylcellulose Matrices  
 
            Hydrophobic ethylcellulose can be used as a matrix former for the formulation of 
sustained-release dosage forms. Batches containing ethylcellulose (F13 to F16) as release 
retardant, extended the release up to 8 -10 hours with initial burst release. As drug polymer 
ratio increased, the release rate was decreased. During dissolution the erosion was 
observed. The results were shown in Table 24 and Figure 8.    
 
Table 24. In-Vitro Release Data of Timolol Maleate from Ethylcellulose Matrices
*
 
 
Time (hours) F13 F14 F15 F16 
1 42.27±0.57 38.7±0.82 35.62±0.71 32.42±0.62 
2 52.47±0.67 47.28±0.69 46.34±0.54 42.83±0.81 
3 64.86±0.73 59.73±0.87 56.84±0.37 54.86±0.42 
4 77.27±0.84 74.95±0.31 72.92±0.84 68.03±1.57 
6 86.63±0.79 81.62±0.64 79.72±0.53 76.26±0.46 
8 98.31±0.52 96.59±0.63 94.56±0.83 85.92±0.75 
10 - - - 97.56±0.71 
12 - - - - 
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*
All values represent mean cumulative percent drug released ± SD (n=3) 
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Figure 8. Release Profiles of Timolol Maleate from Ethylcellulose Matrices 
 
 
Drug Release from Kollidon-SR Matrices  
               Kollidon-SR based formulations (F17 to F20) have shown initial burst release 
with sustaining the release up to 8-10 hours. The results of release studies were given in 
Table 25 and Figure 9. 
 
Table 25. In-Vitro Release Data of Timolol Maleate from Kollidon-SR Matrices
*
 
 
Time (hours) F17 F18 F19 F20 
1 44.24±0.83 41.09±0.73 39.72±0.88 34.84±1.37 
2 55.75±0.79 52.74±0.88 48.43±0.45 42.37±0.98 
3 67.26±1.80 64.89±0.62 60.93±0.61 54.93±0.74 
4 77.84±0.33 75.29±1.60 72.48±0.83 67.82±0.53 
6 89.34±0.86 84.73±0.57 81.76±0.74 78.05±0.71 
8 97.89±0.94 94.98±0.62 92.72±0.48 89.83±0.92 
10 - - - 97.94±0.83 
12 - - - - 
*
All values represent mean cumulative percent drug released ± SD (n=3) 
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  Figure 9. Release Profiles of Timolol Maleate from Kollidon-SR Matrices 
 
 
Drug Release from Combination of HPMC K100M and EC Matrices  
               Batches containing combination of HPMC K100M and ethylcellulose (F21 to 
F25) have shown better release profiles (Table 26 and Figure 10). There was no burst 
release observed with formulations F21 to F23, and release was extended up to 10 to 12 
hours. As the ethylcellulose concentration increases the drug release was decreased further 
in formulations F24 and F25. They prolonged the release for 8 hours only. Batch F23 was 
found to be optimum, as it shown similar release pattern as that of theoretical release 
profile. 
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Table 26. In -Vitro Release Data of Timolol Maleate from Tablets Containing HPMC 
K100M CR and Ethylcellulose
*
 
Time (hours) F21 F22 F23 F24 F25 
1 27.06±0.85 28.73±0.97 25.38±1.54 31.86±1.37 32.23±1.15 
2 40.68±0.93 42.24±0.89 35.09±1.65 44.35±1.52 47.67±1.73 
3 54.27±1.29 55.85±1.17 51.93±1.69 59.83±1.46 64.83±1.58 
4 66.82±1.48 66.38±1.42 62.15±1.99 70.82±1.04 75.38±1.01 
6 80.72±1.79 83.35±1.73 73.88±2.01 87.43±1.96 89.25±1.90 
8 88.25±1.88 90.10±1.92 81.09±2.92 94.64±1.09  98.63±0.97 
10 95.17±2.38 98.43±2.05 87.04±2.48 - - 
12 - - 97.21±2.59 - - 
 
*
All values represent mean cumulative percent drug released ± SD (n=3) 
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 Fig. 10. Release Profiles of Timolol Maleate from Tablets Containing HPMC 
                     K100M CR and Ethylcellulose 
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Drug Release from Combination of HPMC K100M and HPMC K15M 
Matrices 
 
 Combination of HPMC K100M and HPMC K15M was extended the release for 10 
hours. No significant change in the drug release was observed with changing the ratio of 
polymers. All the batches (F26 to F30) have shown burst release also. Data was given in 
Table 27 and Figure 11. 
Table 27.  In-Vitro Release Data of Timolol Maleate from Tablets Containing 
HPMCK100M and HPMC K15M
*
 
Time 
(hours) 
F26 F27 F28 F29 F30 
1 31.25±0.83 32.82±0.95 32.86±0.64 33.55±0.86 34.20±0.38 
2 38.28±0.76 42.71±0.88 44.83±0.58 45.91±0.77 47.04±0.46 
3 53.88±0.58 56.36±0.72 57.73±0.37 59.45±0.73 61.37±0.39 
4 66.46±0.87 67.83±0.46 69.38±0.74 71.24±0.56 74.27±0.48 
6 74.25±0.56 76.25±0.55 76.54±0.83 79.83±0.49 81.38±0.64 
8 83.89±0.58 85.93±0.74 86.25±0.57 88.28±0.68 89.36±0.56 
10 90.63±0.63 93.06±0.67 95.84±0.68 96.09±0.47 97.23±0.84 
12 - - - - - 
*
All values represent mean cumulative percent drug released ± SD (n=3) 
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                Figure 11. Release Profiles of Timolol Maleate from Tablets Containing  
                            HPMCK 100M and HPMC K15M 
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                Out of total 30 batches, the drug release was extended up to 12 hours for the 
formulations F12 and F23. So, these two formulations selected for further studies like 
kinetic data analysis and similarity factor analysis. 
Kinetic analysis of dissolution data 
         The release rate kinetic data for the F12 and  F23 is shown in Table 30 and Table 31 
respectively. As shown in Figures 14-18, drug release data was best explained by first 
order equation, as the plots showed the highest linearity (r
2
 = 0.9955), followed by 
Hixson-Crowell (r
2
 = 0.9800) and Higuchi’s equation (r
2
 = 0.9661). As the drug release 
was best fitted in first order kinetics, indicating that the rate of drug release is 
concentration dependent. Higuchi’s kinetics explains why the drug diffuses at a 
comparatively slower rate as the distance for diffusion increases. The applicability of the 
formulation to the Hixson –Crowell cube root law indicated a change in surface area and 
diameter of the tablets with the progressive dissolution of the matrix as a function of time. 
Mechanism of drug release 
               As shown in Figure 17, the corresponding plot (log cumulative percent drug 
release vs time) for the Korsmeyer-Peppas equation indicated a good linearity (r
2
 = 
0.9741). The diffusion exponent n was 0.66, which appears to indicating a coupling of the 
diffusion and erosion mechanism (Anomalous diffusion) and may indicate that the drug 
release was controlled by more than one process. 
Table 28.Drug Release Kinetics of Batch (F12) Matrix Tablets
* 
 
Zero order First order Higuchi Hixson-
Crowell 
Korsmeyer-Peppas 
r
2 
K0 (h
-1
) r
2
 K1 (h
-
1
) 
r
2
 KH  (h
-1/2
 
) 
r
2
 KHC (h
- 1/ 
3
) 
r
2
 n KKP (h
-n
) 
 
0.8461 
5.188 0.8665 0.1890 0.9335 24.877 0.9695 0.2461 0.9911 0.56 0.4283 
* 
 r
2
 = Correlation coefficient; K = Kinetic constant; n= Diffusional exponent. 
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Table 29.Drug Release Kinetics of Optimized (F23) Matrix Tablets
* 
 
Zero order First order Higuchi Hixson-
Crowell 
Korsmeyer-Peppas 
r
2 
K0 (h
-1
) r
2
 K1 (h
-
1
) 
r
2
 KH  (h
-1/2
 
) 
r
2
 KHC (h
- 1/ 
3
) 
r
2
 n KKP (h
-n
) 
 
0.8985 
5.881 0.9955 0.2012 0.9661 27.839 0.9800 0.1997 0.9741 0.66 0.3238 
* 
 r
2
 = Correlation coefficient; K = Kinetic constant; n= Diffusional exponent. 
         
 
 
 
 
 
 
 
 
 
                
 
 
 
 
              
 
 
Figure 12. Zero Order Graph of Optimized Formulation (F23) 
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                       Figure 13. First Order Graph of Optimized Formulation (F23) 
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                        Figure 14. Higuchi Plot of Optimized Formulation (F23) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Figure 15. Korsmeyer-Peppas Graph of Optimized Formulation (F23) 
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                Figure 18.  Hixson-Crowell Plot of Optimized Formulation (F23) 
 
Figure.16:Hixson-Crowell  Plot of Optimized Formulation (F23) 
Similarity factor analysis 
Similarity factor results for the batches F12 and F23 were given in Table 32.  
Similarity factor analysis between F23 tablets and theoretical release has shown an f2 
factor greater than 50 at each time point with an average value of f2 factor 80.18. Incase of 
F12 tablets, an average value of f2 factor was greater than 50, but at the 3rd and 4th hours 
f2 factor was less than 50. 
The in-vitro release behaviour of F12, F23 batches of tablets were compared with 
the theoretical release profile. A close relationship was observed between F23 formulation 
and theoretical release patterns, compared to a relationship between F12 and theoretical 
release patterns (Figure 19). 
So, F23 was considered as optimized formulation, as these tablets did not show any 
burst release and extended the release for 12 hours with similar release pattern to that of 
theoretical release profile. 
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Table 30. Similarity Factor Analysis 
 
                                           Average % Drug Release                                  f2  factor     
Time (hrs) Theoretical 
release 
F12 F23 F12
 
F23* 
1 26.16 34.93 25.38 73.03 99.09 
2 33.08 49.86 35.09 59.62 95.05 
3 40.00 66.97 51.93 49.47 66.77 
4 46.92 76.82 62.15 47.25 61.66 
6 60.76 81.87 73.88 64.79 64.79 
8 74.60 89.89 81.09 54.73 78.84 
10 88.44 93.07 87.04 61.58 97.31 
12 99.00 98.07 97.21 66.72 77.99 
* Average value of f2 factor   = 80.18 
 
 
 
0
20
40
60
80
100
0 2 4 6 8 10 12
Time (hours)
C
u
m
u
la
ti
v
e
 %
 D
ru
g
 R
e
le
a
s
e
F23
Theoretical
F12
 
 
                      Figure 17. Comparative In-Vitro Drug Release Profile  
 
               Swelling and erosion behaviour, FTIR studies, and stability study were 
performed on optimized formulation (F23). 
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Determination of swelling and eroding behavior 
 
             Since the rate of swelling and erosion is related and may affect the mechanism and 
kinetics of drug release, the penetration of the dissolution medium and the erosion of the 
hydrated tablets were determined. Simultaneously with the swelling study, the percentage 
erosion of polymer was determined. The percentage swelling and erosion of optimized 
tablet was shown in Figures 20 and 21, and data was given in Table 33. Maximum 
swelling was observed in first 2 hours and gradually it was decreased with simultaneous 
erosion of polymer. 
            
 
              Table 31. Swelling and Erosion Study of Optimized Formulation (F23) 
 
Time (hours) % Swelling % Erosion 
1 76.43 18.72 
2 128.35 24.37 
3 84.57 28.73 
4 71.94 42.62 
6 60.64 56.83 
8 49.53 64.52 
10 36.72 72.41 
12 24.83 93.29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
                            Figure 18. Swelling Study of Optimized Formulation (F23) 
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Figure 19. Erosion Study of Optimized Formulation (F23) 
 
 
Fourier transform infrared spectroscopy (FTIR) 
           FTIR spectra of the drug and the optimized formulation were recorded in range of 
4000-400 cm
-1
. Timolol maleate showed some prominent and characteristic peaks. The 
peaks at 3305 and 1120 cm
-1
 were due to stretching vibrations of O-H and C-O bond of 
secondary alcohol respectively. Peaks at 2967, 2856, and 1707 cm
-1
 could be assigned to  
the asymmetric C-H stretching of CH3 group, symmetric C-H stretching of CH2 group, and 
C=N stretching respectively.  In the optimized formulation, the presence of all the 
characteristic peaks of the timolol maleate indicates that no interaction was occurred 
between the drug and the excipients. 
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FTIR spectrum of Timolol Maleate 
 
 
Chapter-7                                                                                                                                    Results  
 
Dept ., of Pharmaceutics , The Erode College Of Pharmacy & Research Institute, Erode  Page 92 
 
 
 
 
 
FTIR Spectrum of optimized formulation(F23) 
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ACCELERATED STABILITY STUDIES 
            The optimized batch of F23 Timolol maleate matrix tablet 120 mg were evaluated 
for accelerated stability studies at 40
0
C / 75 % RH condition. The stability details / results 
are presented as below. 
The stability studies on Timolol maleate matrix tablet 120 mg in HDPE container 
at 40
0
C / 75 % RH for 2 months were conducted as per ICH protocol. After the specified 
time period      (1 month and 2 months), the samples were unloaded from the stability 
chambers and were tested for any physical or chemical changes. Also the tests for 
dissolution and assay were conducted to assess the stability of product. 
Storage Condition: 40
0
C / 75 % RH  
Pack: HDPE Container 
         Storage Period: 1 month and 2 months 
             Stability studies were carried out for optimized formulation they had showed good 
stability and the values were within permissible limits and the values are tabulated below 
 Table no.32 Accelerated stability studies data: 
               
S.N
o 
Test Specifications Initial After 1 
month 
After 2 
months 
1 Description White/Off-white coloured tablets Complies Complies Complies 
2 Identification The retention time of major peak 
in the chromatogram of the assay 
preparation corresponds to that in 
the chromatogram of the standard 
preparation as obtained in the 
assay. 
Complies Complies Complies 
3 Dissolution (In 
purified water) 
NLT 80% release after 12 hours 
 
98.3% 97.8% 97.5% 
5 Assay (By uv) NLT 95.0 percent and NMT 
105.0 percent 
99.16% 98.77% 98.69% 
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The results for dissolution and assay are summarized below. 
Dissolution: 
               No significant change was observed in the percentage drug dissolved after a 
storage period of 1 month at 40
0
C / 75 % RH and 2 months at 40
0
C / 75 % RH for Timolol 
maleate  matrix tablet 120 mg.  
 
 
  Tabel:20 
 
 
 
 
 
 
    
                               
 
 
  Fig 8.13 - Accelerated stability studies – Dissolution 
 
 
Assay: 
                  No significant change was observed in the assay value of Timolol maleate 
matrix tablet 120 mg, after a storage period of 1 month at 40
0
C / 75 % RH and 2 months at 
40
0
C / 75 % RH. 
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  Tabel:21  
 
 
 
 
  
 
 
 
 
 
 
 
 
Inference: 
             From the above data it was evident that there was no significant change in the 
physical and chemical parameters of Timolol Maleate matrix tablet during the stability 
studies conducted at 40°C & 75%RH for1 month period and 2 months at 40°C & 75%RH. 
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DISCUSSION 
   Oral drug delivery system represents one of the frontier areas of controlled drug 
delivery system; such dosage forms are having a major advantage of patient compliance. 
The Extended release dosage form that allows at least a twofold reduction in dosage 
frequency as compared to that drug presented as an immediate-release (conventional) 
dosage form. 
 A controlled release matrix dosage form is defined "as one for which the drug-
release characteristics of time course and/or location are chosen to accomplish 
therapeutic or convenience objectives not offered by conventional dosage forms. 
Timolol maleate is a nonselective beta-adrenergic receptor blocking agent used 
for the treatment of Hypertension. The therapeutic concentration required for this purpose 
is 20-40mg/day. The therapeutic dose is needed to be maintained for 12 hrs. The 
conventional doses release the entire drug in just few minutes and therefore the 
therapeutic concentrations are maintained for a short period of time generating a need for 
administration of another dose. Therefore a sustained release formulation of timolol 
maleate  which would release the drug over a time period of 12 hrs is beneficial. 
The objective of the study is to formulate and evaluate Timolol maleate extended 
release matrix tablets. To enhance the release, an attempt was made to prepare the 
controlled release matrix tablet using polymers such as HPMC K15 M, Polyethylene 
Oxide, Ethyl Cellulose, Kollidion-SR , and HPMC K100M. 
Hence, the present research work was to study systematically the effect of 
formulation variables on the release of Timolol maleate. 
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PREFORMULATION PARAMETERS: 
Determination of λ max of Timolol maleate: 
On the basis of preliminary identification test it was concluded that the drug 
complied the preliminary identification. From the scanning of drug, it was concluded that 
the drug had λmax of 295 nm, which was equal to 295 nm as reported. Also, an IR 
spectrum was concordant with the reference spectrum of Timolol maleate. 
Preparation of standard calibration curve of Timolol maleate: 
From the standard curve of Timolol maleate (Table No. 17, Graph 3), it was 
observed that the drug obeys beer’s law in concentration range of 5 – 50 µg/ml in 0.1N 
HCL and phosphate buffer ph 6.8. The linear regression equation generated was used for 
the calculation of amount of drug.  
Determination of IR spectrum of Timolol maleate: 
 Physical mixture of drug and polymer was characterized by FTIR spectral analysis for 
any physical as well as chemical alteration of the drug characteristics. From the results, it 
was concluded that there was no interference in the functional group as the principle 
peaks of the Timolol maleate were found to be unaltered in the drug-polymer physical 
mixture, indicating they were compatible chemically. 
DRUG EXCIPIENT COMPATABILITY STUDIES 
Drug-Excipient compatibility studies form an important part of Preformulation 
studies for the determination of interaction between drug and excipient. It is determined 
after storage of specific time period by using suitable analytical techniques and the results 
are indicating that there is no interaction between drug and excipients. 
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FORMULATION DESIGN: 
Formulation of the controlled release matrix tablet:   
 The use of hydrophilic polymers is currently the most applied method in 
controlling the release of drugs from oral pharmaceutical dosage forms. 
Hydroxypropylmethylcellulose (HPMC) is a polymer frequently used in formulation of 
controlled release devices, for its ability to form rapidly a gel layer at the matrix 
periphery exposed to aqueous media. The difference in the molecular weight and 
viscosity of HPMC polymer influence the release of the drug. 
Kollidion-SR, Ethyl cellulose and polyethylene oxide are used as polymers for the 
extended release of the drug 
Microcrystalline cellulose and lactose  are used as the tablet diluent and binding 
agent. 
 2 % of Magnesiumsterate added in extra granular as a lubricant. 
EVALUATION PARAMETERS: 
Physicochemical evaluation: 
The prepared tablets were subjected to preliminary characterization such as 
hardness, thickness, % weight variation, friability and drug content. The evaluated 
parameters were within acceptable range for all the   formulations. The values are 
indicated in Table No. --.  
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Table No. 43: Range for value of preliminary characterization of formulations 
Parameters Range 
Hardness (kg/cm
2
) 4.08±0.8 – 6.16±0.7 
Thickness (mm) 2.95 ± 0.75 – 3.32 ± 0.65 
Weight variation (%) 118.6±0.41 – 122.9±0.9 
% Friability 0.12 - 0.77 
Drug content (%) 90.35 – 102.87 
In vitro drug release profile: 
The dissolution test for in vitro release of  all the formulation , were carried out 
using USP Type –II(paddle ).A  revolving at 100 rpm with phosphate buffer  pH -6.8 
dissolution media was used. The study carried out at 37±0.5° drug  release as shown in  
tables from 
The results are described as: 
The formulations F1, F2, F3 and F4 are formulated with different concentrations 
of HPMCK15M with 1:0.5,1:1,1:1.5 and 1:2 respectively. And the release of the drug 
was faster. In all these formulations 90% of the drug release was with in 10 hours. the 
desired f2 value was not achieved.  
The formulations F5, F6, F7 and F8 are formulated with different concentrations 
of Polyethylene Oxide with 1:0.5,1:1,1:1.5 and 1:2 respectively. And the release was 
highly sustaining as the concentration of the polymer is increasing. In all these 
formulations the release was  more than 97% at the end of the 8
th 
hour. And the desired f2 
values are not achieved. 
The Formulations containing HPMC K100M (F9 to F12) have shown initial burst 
release and extended the release for 8 to 12h. As the drug polymer ratio increased to 1:2 
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(F12), the kinetics of release decreased (98.97% at 12h). The drug release was slower 
from matrices containing HPMC K100M compared to HPMC K15M. This may be due to 
structural reorganization of HPMC. Increase in concentration and viscosity of HPMC 
may result in increase in the tortuosity or gel strength of the polymer. The desired f2 
values are not achieved. 
The formulations containing ethylcellulose (F13 to F16) as release retardant, 
extended the release up to 8 -10 hours with initial burst release. As drug polymer ratio 
increased, the release rate was decreased. During dissolution the erosion was observed. 
The formulations containing Kollidon-SR b (F17 to F20) have shown initial burst 
release with sustaining the release up to 8-10 hours. The release is 95.04% at 10 hrs and 
desired f2 values are not obtained. 
The formulations containing combination of HPMC K100M and ethylcellulose 
(F21 to F25) have shown better release profiles. There was no burst release observed with 
formulations F21 to F23, and release was extended up to 10 to 12 hours. As the 
ethylcellulose concentration increases the drug release was decreased further in 
formulations F24 and F25. They prolonged the release for 8 hours only. Batch F23 was 
found to be optimum, as it shown similar release pattern as that of theoretical release 
profile. 
The formulations containing combination of HPMC K100M and HPMC 
K15M(F26 to F30)  was extended the release for 10 hours. No significant change in the 
drug release was observed with changing the ratio of polymers. All the batches have 
shown burst release also. 
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DATA ANALYSIS: 
  The curve fitting results of the release rate profile of the designed formulations 
gave an idea on the mechanism of drug release. 
Based on the “n” values are ranging from0.56-0.66 for all the formulations 
formulation, the drug release was found to follow Anomalous (non-Fickian) diffusion. 
This value indicates a coupling of the diffusion and erosion mechanism (Anomalous 
diffusion) and indicates that the drug release was controlled by more than one process. 
            Also, the drug release mechanism was best explained by zero order, as the plots 
showed the highest linearity (r
2
 = 0.8985), As the drug release was best fitted in zero 
order kinetics, it indicated that the rate of drug release is concentration independent. 
Criteria for selection of optimized formulation: 
            Similarity factor analysis between F23 tablets and theoretical release has shown 
an f2 factor greater than 50 at each time point with an average value of f2 factor 80.18. 
Incase of F12 tablets, an average value of f2 factor was greater than 50, but at the 3rd and 
4th hours f2 factor was less than 50. 
          The in-vitro release behaviour of F12, F23 batches of tablets were compared with 
the theoretical release profile. A close relationship was observed between F23 
formulation and theoretical release patterns, compared to a relationship between F12 and 
theoretical release patterns. 
          So, F23 was considered as optimized formulation, as these tablets did not show any 
burst release and extended the release for 12 hours with similar release pattern to that of 
theoretical release profile. 
 Hence the above said formulations were selected for further evaluation such as 
accelerated stability studies. 
Stability Studies: 
        Stability studies were carried out for optimized formulation they had showed good 
stability and the values were within permissible limits.  
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SUMMARY AND CONCLUSION 
Summary: 
          Timolol maleate is a nonselective beta-adrenergic receptor blocking agent. It 
possesses an asymmetric carbon atom in its structure and is provided as the levo isomer. 
As the conventional doses release the Timolol maleate in just few minutes and 
therefore the therapeutic concentrations are maintained for a short period of time 
generating a need for administration of another dose 
Therefore an attempt is made to maintain the therapeutic concentration for longer 
period of time. This is achieved by developing controlled release drug delivery system. 
These controlled release matrix tablets mainly prepared for release of the drug for longer 
period of time i.e., 12 hours and utilizing the drug to full extent avoiding unnecessary 
frequency of dosing. 
For the formulation of controlled release matrix tablet HPMC K 15M , HPMC 
K100M,Ethyl cellulose, PVP, Kollidion-SR was used as matrix forming agents. Other 
excipients used are microcrystalline cellulose and lactose(diluents), Magnesium stearate 
(lubricating agent). Fourier transform Infrared spectroscopy confirmed the absence of any 
drug/polymers/excipients interactions. 
 The prepared controlled release tablets were evaluated for hardness, Weight 
variation, thickness, friability, drug content uniformity, In-vitro dissolution studies. F23 
formulation showed good evaluation studies and a controlled drug release. The dissolution 
profiles of all the formulations are compared with theoretical values by calculating the f2 
values. F23 has obtained the highest f2 value (77.99) hence F23 is considered to be the 
optimized formulation. Stability studies were carried out for F23 formulation and they had 
showed good stability when stored at accelerated stability state as per the ICH guideline 
and the values were with in a permissible limits.  
           Matrix tablets were compressed without any problem and do not require any change 
in ratio of excipients in formulation. Results of the present study demonstrated that 
combination of both hydrophilic and hydrophobic polymers could be successfully 
employed for formulating sustained-release matrix tablets of timolol maleate.  
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          All the formulations containing drug to polymer ratio 1:2 and MCC as a diluent 
extended the drug release for 8 to 12 hours. Lactose containing formulations have shown 
faster drug release.  
          Among  the hydrophilic matrix formers, the rate of drug release was in the following 
order 
PEO > HPMC K15M > HPMC K100M. 
         PEO containing formulations (F6-F8) have did not show initial burst release.  
 
         The drug release rate was almost similar with hydrophobic EC and plastic Kollidon-
SR. 
          
         The drug release rate was slower with the tablets containing combination of both 
hydrophilic HPMC K100M and hydrophobic EC polymers compared to with that of 
combination of 2 hydrophilic polymers (HPMC K100M and K15M). 
           Compared to direct compression, wet granulation method was found to be better 
choice to extend the drug release for 12 hours. 
         Majority of formulations have released the drug by non-Fickian diffusion. 
           Erosion was the dominating release mechanism for the formulations containing 
Kollidon-SR or EC. 
           It was observed that Formulations F23 retained the drug release up to 24 hrs. 
All formulations were subjected for four different models viz. Zero order, First order, 
Higuchi matrix and Peppas model equations and all the formulations best fit in to the 
Peppas model by giving the values of diffusional exponent (n) in the range of 0.56-0.66 
that indicate the formulation had release the drug by diffusion followed by erosion 
mechanism.  
     It was revealed that polymers and lactose ratios had significant influence on drug 
release. Thus it is summarized that stable dosage form can be developed by timolol 
maleate for sustained release matrix tablets. 
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Conclusion: 
  The aim of the present study was to develop an controlled release formulation of 
Timolol maleate to maintain constant therapeutic levels of the drug for over 12 hrs. 
            Timolol maleate controlled release matrix tablets are prepared by wet granulation 
method with different grades of HPMC.  
              An efficient extended release formulation of Timolol maleate could be designed 
as controlled release tablets. The optimised formulation (F23) was developed by using 
HPMC K100M and Ethyl cellulose(1:1).  
 The results of dissolution studies indicated that formulation F-23, the most 
successful of the study, exhibited drug release pattern very close to theoretical release 
profile.  The designed matrix tablets F-23 of timolol maleate, which release 25.38% 
respectively of drug in the first hour and extend the release upto 12 hours, can overcome 
the disadvantages associated with conventional tablets formulation of Timolol Maleate 
tablets. Regulated drug release in zero order kinetics attained with this formulation. 
 
The release process involves anomalous diffusion mechanism or diffusion coupled 
with erosion, as indicated by the n value of 0.66 in Korsmeyer’s plot.  There was an 
alteration in the surface area and diameter of the tablets with the progressive dissolution of 
the matrix as a function of time, as indicated in Hixson-Crowell plot. FTIR studies 
combined with stability studies proved the integrity of the developed matrix tablets. 
Hence it can be concluded that twice a daily controlled release matrix tablet of 
Timolol maleate having satisfactory extended release profile which may provide an 
increased therapeutic efficacy. The developed formulation overcome and alleviates the 
drawback and limitation of extended release preparations.  
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